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Dansk	resume	
	Multipel	sklerose	(MS)	er	den	hyppigste	neurologiske	sygdom	hos	unge	voksne.	Prævalensen	er	tredoblet	 i	perioden	fra	1950	til	2005,	overvejende	drevet	af	en	stigning	 i	hyppighed	hos	unge	kvinder.	MS	er	en	inflammatorisk	sygdom	i	centralnervesystemet	(CNS)	som	medfører	demyeliniserende	skade	på	aksoner	og	neuroner.	Sygdommen	kan	 inddeles	 i	 to	undertyper:	en	 attakvis	og	 en	progressiv	 fænotype.	Begge	 fænotyper	 er	karakteriseret	 ved,	 at	patienten	over	 tid	udvikler	 fokale	neurologiske	 symptomer	og	udviser	kognitivt	dekline	 samt	kronisk	fatigue.	Det	 sidste	opleves	 af	mange	patienter	 som	det	 værste	 symptom	ved	deres	 sygdom.	Tab	af	intellektuelle	evner,	fatigue	og	aftagende	gangfunktion	er	blandt	de	hyppigste	årsager	til	 pensionering	 eller	 reduceret	 erhvervsevne,	 hvorfor	 de	 udgør	 en	 betydelig	 individuel	 og	socioøkonomisk	 byrde.	 Aktuelt	 tilgængelige	 behandlinger	 reducerer	 attakraten,	handicapprogression,	 og	 enkelte	 behandlinger	 synes	 at	 stabilisere	 patientens	 kognitive	niveau	og	 lindre	 fatigue.	 Spørgsmålet	om	kognitive	 attakker	 findes	 er	kontroversielt	 og	har	været	genstand	for	intens	debat	i	de	senere	år.	Mange	patienter	oplever	voldsom	derudover	også	fatigue	i	forbindelse	med	attak.		Fatigue	er	det	hyppigste	symptom	hos	patienter	med	MS	(65-95%)	og	opleves	hos	mere	end	hver	tredje	som	det	sværeste	symptom	(≈40%).	Der	findes	pt.	 ikke	noget	objektivt	mål	eller	en	defineret	guldstandard	til	måling	af	fatigue.	Derfor	er	selvrapportering	aktuelt	den	eneste	anvendelige	 målemetode.	 Fatigue	 Scale	 for	 Motor	 and	 Cognitive	 Functions	 (FSMC)	 er	 et	nyudviklet	spørgeskema	som	er	valideret	i	en	tysk	MS-kohorte.	
	 6	
Dette	 ph.d.-studies	 resultater	 sammenlignes	 med	 valideringsstudiernes	 data,	 hvorfor	 vi	anbefaler	den	danske	version	af	FSMC	til	klinisk	praksis	og	akademisk	brug	i	Danmark.		MS-patienters	 kognitive	 status	 kan	 evalueres	 gennem	 en	 standardiseret	 neuropsykologisk	test.	Denne	proces	er	dog	 tidskrævende	og	bekostelig,	hvorfor	den	 ikke	er	anvendelig	 i	MS-klinikkernes	daglige	praksis.	Der	er	udviklet	testbatterier	til	screening,	som	kan	udføres	af	en	trænet	læge	eller	sygeplejerske	inden	for	30	min.,	hvilket	ligeledes	begrænser	muligheden	for	implementering	 af	 kognitiv	 screening	 flere	 gange	 årligt.	 The	 Multiple	 Sclerosis	Neuropsychological	 Screening	 Questionnaire	 (MSNQ)	 er	 et	 nyudviklet	 spørgeskema	 til	udfyldning	af	både	patient	og	nærmeste	pårørende	med	henblik	på	screening	for	udvikling	af	demens.	 Spørgeskemaet,	 der	 er	 valideret	 på	 amerikansk	 engelsk,	 argentinsk	 spansk	 og	hollandsk,	er	foreslået	som	et	brugbart	og	omkostningseffektivt	screeningsværktøj.	Da	vi	ikke	har	kunnet	demonstrere	korrelation	imellem	resultater	af	MSNQ	og	af	neuropsykologiske	test,	konkluderer	 vi,	 at	MSNQ	 ikke	er	brugbar	 til	 screening	af	danske	MS-patienter	 for	kognitive	problemer.	Vores	data	 indikerer	 at	 skalaen	er	påvirkelig	 af	 kulturelle	og	 sproglige	 forskelle	samt	 depressive	 symptomer	 hos	 patienterne.	 Det	 kan	 ikke	 udelukkes,	 at	 positiv	publikationsbias	forklarer	fraværet	af	negative	data	om	MSNQ.	Symbol	Digit	Modalities	Test	(SDMT)	er	en	kort	objektiv	test	udviklet	til	screening	for	kognitiv	påvirkning	af	proceshastighed	og	visuospatial	hukommelse.	Testen	lader	sig	let	implementere	i	 daglig	 klinisk	 praksis,	 da	 den	 uden	 besvær	 kan	 udføres	 af	 en	 sundhedsfaglig	 person	 på	mindre	end	5	min.	Der	savnes	undersøgelser	af,	hvordan	resultaterne	påvirkes	ved	gentagen	testning,	og	en	læringseffekt	ved	gentagen	testning	kan	ikke	udelukkes.		
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Nærværende	 studie	 viser	 en	 signifikant	 forbedring	 af	 SDMT-scoren,	 når	 den	 udføres	månedligt	 i	 en	 kohorte	 af	 MS-patienter	 i	 behandling	 med	 natalizumab.	 Vores	 gentest	 af	patienter	med	 en	 anden	 version	 af	 SDMT	efter	 to	 år	 demonstrerer,	 at	 scoren	 returnerer	 til	baseline,	hvilket	 formentlig	er	udtryk	 for	en	 læringseffekt	ved	gentagen	 testning.	Vi	påviser	ligeledes	en	stabilisering	af	kognitiv	status	under	og	efter	2	års	behandling	med	natalizumab.			 	
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English	summary	
	Multiple	 sclerosis	 (MS)	 is	 the	 most	 frequent	 neurological	 disease	 in	 young	 adults.	 Its	prevalence	has	increased	by	close	to	threefold	from	1950	to	2005,	predominantly	due	to	its	increasing	incidence	in	younger	women.	MS	is	an	inflammatory	disease	of	the	central	nervous	system	 (CNS)	 that	 leads	 to	 demyelination	 and	 axonal/neuronal	 damage.	MS	 has	 two	major	subtypes,	a	relapsing	and	a	progressive	phenotype,	both	characterized	by	 focal	neurological	symptoms,	cognitive	decline,	and	chronic	fatigue.	Even	without	relapses,	these	symptoms	can	be	 severe	 and	 disabling.	 Cognitive	 decline,	 fatigue,	 and	 walking	 disabilities	 are	 the	 most	frequent	 reasons	 for	 retirement;	 the	 individual	 and	 socioeconomic	 consequences	 are	 thus	substantial.	 Current	 treatments	 can	 reduce	 relapse	 rates	 and	 the	 progression	 of	 disability;	some	appear	to	stabilize	cognitive	performance,	while	a	few	also	have	some	effect	on	fatigue.	The	role	of	cognitive	decline	as	a	sign	of	relapse	or	drug	 failure	has	recently	been	 intensely	debated.	MS	patients	experience	 fatigue	as	 the	most	 frequent	 symptom,	and	often	 the	most	severe.	Many	patients	experience	severe	fatigue	along	with	a	relapse	or	disease	progression	but	also	without	apparent	signs	of	disease	activity.		No	 objective	 test	 has	 provided	 a	 reliable	 measure	 of	 fatigue	 in	 MS,	 and	 patient-reported	outcomes	 are	 currently	 the	 only	 way	 to	 monitor	 fatigue.	 The	 Fatigue	 Scale	 for	 Motor	 and	Cognitive	 Functions	 (FSMC)	 is	 a	 patient-reported	 questionnaire	 validated	 in	 a	 German	 MS	cohort.	We	recently	translated	the	scale	into	Danish.	The	results	presented	in	this	Thesis	are	similar	 to	 those	 of	 the	 original	 validation	 study;	 we	 therefore	 recommend	 the	 use	 of	 the	Danish	version	of	the	FSMC	in	clinical	settings	and	for	scientific	purposes.	
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	The	cognitive	performance	of	MS	patients	can	be	measured	by	a	neuropsychological	test,	but	this	is	time-consuming	and	hardly	feasible	in	everyday	practice.	Short	cognitive	test	batteries	have	 been	 developed	 for	 physicians	 and	 nurses	 to	 screen	 cognitive	 impairment	 in	MS.	 The	Multiple	 Sclerosis	 Neuropsychological	 Screening	 Questionnaire	 (MSNQ)	 was	 created	 for	screening	cognitive	function	in	MS	patients	by	their	relatives	(informants).	The	questionnaire	was	 successfully	 developed	 and	 validated	 in	 American	 English,	 and	 later	 validated	 in	Argentine	 Spanish,	 and	 has	 been	 proposed	 as	 a	 rapid	 and	 cost-effective	 screening	 tool.	However,	as	the	MSNQ	scores	obtained	in	our	study	of	Danish	MS	patients	did	not	correlate	with	neuropsychological	assessment,	we	conclude	that	it	does	not	offer	a	valid	and	sensitive	screening	tool	for	cognitive	impairment	in	Danish	MS	patients.	Our	data	thus	emphasize	the	importance	of	validation	in	different	languages,	since	instruments	may	be	sensitive	to	cultural	and	linguistic	differences.	In	addition,	the	publication	of	exclusively	positive	results	obtained	by	validation	of	new	self-reported	scales	may	create	a	bias,	and	dependence	of	self-reported	questionnaires	on	language	and	culture	are	going	to	be	missed.			The	 Symbol	 Digit	 Modalities	 test	 (SDMT)	 is	 a	 brief,	 objective	 screening	 tool	 for	 cognitive	impairment	that	can	be	administered	by	a	healthcare	professional	 in	 less	 than	five	minutes.	The	test	mainly	measures	information	processing	speed	and	visuospatial	memory.	SDMT	is	an	ideal	rapid	screening	tool	for	regular	usage	due	to	its	easy	application.	However,	a	potential	learning	 effect	 of	 repeated	 administration	may	 limit	 its	 value.	 Our	 examination	 of	monthly	SDMT	scores	in	MS	patients	treated	with	natalizumab	demonstrated	significant	improvement,	with	scores	increasing	when	tested	monthly.	
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However,	 by	 using	 a	 different	 version	 of	 SDMT	 after	 two	 years,	 the	 scores	 returned	 to	baseline.	We	conclude	that	frequent	application	of	the	SDMT	results	in	a	significant	learning	effect	that	should	be	considered.	Our	study	also	indicates	that	cognitive	levels,	as	measured	by	SDMT,	are	stable	throughout	the	course	of	natalizumab	treatment.			 	
	 11	
Abbreviations	
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Introduction		
Multiple	sclerosis	(MS)	is	the	third	most	frequent	disease	of	the	central	nervous	system	(CNS)	after	
migraine	 and	 epilepsy	 1,	 2.	 Northern	 Europe	 is	 a	 high	 endemic	 region,	 with	 Denmark	 having	 a	
prevalence	of	 approximately	155/100,000	people	 (95%	confidence	 interval	 (CI):	 149–160).	 From	
1950	to	2005,	 the	prevalence	has	 increased	by	a	 factor	close	to	three,	predominantly	due	to	an	
increase	 in	 its	 incidence	 in	 younger	women,	 as	 the	 female-to-male	 ratio	 increased	 from	1.31	 in	
1950	to	2.02	in	20053,	4.	
MS	is	a	chronic	inflammatory	demyelinating	disease	of	the	CNS	that	ultimately	leads	to	axonal	and	
neuronal	degeneration.	Disease	onset	is	usually	in	early	adulthood	(age	20–40	years);	overall,	the	
lifespan	is	shortened	by	five	to	ten	years	compared	to	the	background	population4.	Recent	studies	
suggest	 that	 the	 incidence	 of	 early	 death	 has	 been	 reduced	 as	 disease-modifying	 treatments	
(DMT)	have	advanced,	because	earlier	diagnosis	has	contributed	to	early	immunotherapy	and	the	
general	 care	of	people	with	MS	has	 improved5.	DMTs	are,	however,	 currently	available	only	 for	
relapsing	 forms	 of	MS6.	 On	 average,	 people	with	MS	 live	 for	more	 than	 35	 years	 from	 time	 of	
diagnosis	to	death5.		
MS	phenotypes		
According	 to	 the	 traditional	 classification	of	MS,	 90%	present	with	 a	 relapsing–remitting	 course	
(RRMS),	 and	 if	 untreated,	 50%	 of	 them	will	move	 on	 to	 a	 secondary	 progressive	 phase	 (SPMS)	
fifteen	years	after	the	onset	of	disease7.	Approximately	10%	of	multiple	sclerosis	patients	present	
with	primary	progressive	multiple	sclerosis	(PPMS).		
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RRMS	 is	 characterized	 by	 clinical	 activity	 (neurological	 symptoms	 and	 signs),	 defined	 as	 fully	 or	
partially	recovering	relapses,	which	may	be	suggested	by,	for	example,	blurred	vision,	paresthesia,	
paresis,	loss	of	bladder	control,	or	walking	disabilities.	No	or	minimal	disease	progression	is	seen	
between	relapses	(remission).	The	first	relapse	is	termed	clinically	isolated	syndrome	(CIS).	Some	
patients	may	meet	the	formal	definition	of	MS	with	a	single	clinical	episode	if	their	MRI	reveals	the	
simultaneous	 presence	 of	 enhancing	 and	 non-enhancing	 lesions.	Most	 patients	 with	 RRMS	will	
eventually	enter	a	secondary	progressive	phase8,	9.	
SPMS	 begins	with	 a	 relapsing-remitting	 course,	 followed	 by	 gradual	worsening	with	 or	without	
occasional	 relapses.	 Phases	 with	 minor	 remission	 and	 disease	 plateaus	 are	 observed.	 The	
transition	from	RRMS	to	SPMS	usually	occurs	10	to	20	years	after	disease	onset.		
PPMS	 is	characterized	by	progressive	disability.	While	relapses	are	rare,	plateaus	and	temporary	
minor	 improvements	 are	 occasionally	 seen.	 Progressive	 MS	 subtypes	 are	 diagnosed	
retrospectively,	based	on	patient	history	and	clinical	evaluation.	A	common	clinical	presentation	of	
PPMS	 is	 a	 spinal	 cord	 syndrome	 with	 progressive	 paraparesis,	 spasticity,	 and	 no	 clear	 sensory	
level.	Compared	with	RRMS,	PPMS	has	a	more	even	sex	distribution	and	later	onset,	usually	two	
decades	later	in	life.	The	course	of	PPMS	tends	to	be	more	aggressive	than	that	of	RRMS4,	10,	11.	
A	recent	update	of	the	MS	subtype	classification	has	suggested	a	two-fold	division	of	the	disease	
into	 relapsing	 and	 progressive	 forms,	 each	 of	 which	 has	 active	 and	 inactive	 stages;11	 this	
classification	may	be	more	appropriate	when	considering	upcoming	biological	 treatments	 	being	
efficient	in	progressive	MS	with	inflammatory	activity12,	13.	
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T-cells	 and	 B-cells	 play	 an	 important	 role	 in	 driving	 CNS	 inflammation,	 especially	 in	 the	 early	
relapsing–remitting	disease	phases.	This	 is	 reflected	 in	 the	 treatment	 response	 to	a	monoclonal	
antibody	 that	 prevents	 lymphocyte	 trafficking	 into	 the	 CNS:	 the	 humanized	 anti-alpha4-integrin	
antibody,	natalizumab,	which	blocks	the	alpha-4	integrin	receptor	on	lymphocytes,	inhibits	binding	
to	the	vascular	cell	adhesion	molecule	(VCAM),	thereby	preventing	 lymphocytes	penetrating	the	
blood–brain	barrier14.	
While	 the	 evaluation	 of	 disease	 activity,	 progression,	 and	 treatment	 outcomes	 has	 previously	
focused	 on	 relapse	 rates	 and	 patient	mobility,	 attention	 over	 the	 last	 two	 decades	 has	moved	
toward	 cognition	 and	 patient-reported	 outcomes	 (PROs).	 Fatigue,	 which	 plays	 a	 major	 role	 in	
quality	of	 life	(QoL),	marital	status,	and	depression,	with	their	attendant	socioeconomic	impacts,	
can	 thus	 be	 measured	 only	 by	 PROs15-17.	 Our	 study	 focuses	 on	 both	 fatigue	 and	 cognition,	
emphasizing	validation	and	the	implementation	of	clinical	testing	and	patient-reported	outcomes	
in	the	MS	clinic.	
Measuring	disease	activity	
Several	of	the	disease-modifying	therapies	(DMTs)	that	have	been	developed	over	the	past	twenty	
years	 reduce	 relapse	 rates	 and	 slow	 the	 development	 of	 disability.	 Recently,	 No	 Evidence	 of	
Disease	Activity	(NEDA)18	was	proposed	as	a	treatment	aim.6	Clinical	rating	tools,	MRI	parameters,	
and	possibly	self-reported	outcomes	may	be	integrated	into	NEDA	outcomes	in	the	future.	While	
criteria	have	been	proposed	(NEDA	3	and	NEDA	4),	no	consensus	about	their	application	has	yet	
been	achieved19.	
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Consistent	 monitoring	 tools,	 such	 as	 rating	 scales	 and	 self-reported	 outcomes,	 are	 therefore	
important	 for	 clinicians.	Most	 of	 the	 currently	 available	 PRO	 scales	 have	been	 validated	only	 in	
English	 or	 other	 major	 languages.	 It	 is	 debated,	 whether	 the	 translated	 versions	 reflect	 the	
originally	intended	outcomes.	Due	to	cultural	and	linguistic	differences,	validation	of	translations	
is	essential	before	their	clinical	application20.	
The	use	of	scales	or	questionnaires	to	measure	symptoms	raises	some	important	questions—for	
example,	 should	 they	 be	 graded	 dichotomously	 or	 with	 a	 numeric	 or	 analog	 scale?	 Could	 a	
standardized	measurement	be	achieved	by	the	patient,	or	a	trained	clinician	is	required?	Are	the	
scales	 biased	 by	 other	 symptoms	 or	 outcomes?	 To	 confirm	 hypotheses,	 physicians	 and	
neurologists	in	particular	prefer	objective	measures	or	paraclinical	findings.	Some	symptoms,	such	
as	 fatigue21	 and	mild	 cognitive	 impairment22	 are,	 however,	 very	 difficult	 to	measure	 by	 formal	
testing.	 Self-reported	 outcomes	 could	 therefore	 supplement	 the	management	 strategy	 in	 these	
important	domains	of	MS.	Outcomes	could	also	function	as	screening	tools	to	help	target	problem	
areas	and	facilitate	effective	communication.	PROs	can	usually	be	performed	in	the	home,	online,	
or	immediately	before	clinical	contact.	
Many	 of	 the	 existing	 PRO	 instruments	 have	 structured	 scales	 with	 different	 items	 that	 enable	
different	perspectives	on	their	domain.	Some	questionnaires	also	include	different	domains,	such	
as	 overall	 fatigue,	 with	 subscales	 for	 cognitive	 and	 physical	 fatigue.	 Construct	 validity	 and	
reliability	are	important	aspects	of	the	validation	of	patient-reported	outcome	scales20,	23-25.	
	 16	
Fatigue	in	MS	and	self-reported	outcome	measures	
Fatigue	 is	 a	 very	 commonly	 reported	 subjective	 symptom	 of	 MS	 (65–95%).	 Patients	 typically	
describe	 it	 as	 the	most	 severe	 symptom26,	27.	 Fatigue	 and	mood	 disorders	 (depression)	 have	 a	
highly	negative	impact	on	QoL28.		
MS	patients	may	experience	fatigue	as	a	range	varying	from	the	normal	tiredness	experienced	by	
healthy	 individuals	 to	more	severe	and	disabling	 forms	 that	are	 likely	 to	 interfere	with	personal	
and	 social	 responsibilities.29	A	major	 challenge	 in	 the	management	of	 fatigue	 is	 the	uncertainty	
over	 its	 definition,	 etiology	 and	 pathophysiology,	 with	 no	 gold	 standard	 existing	 among	
researchers	 and	 clinicians.21	 Studies	 that	 examine	 functional	 brain	magnetic	 resonance	 imaging	
and	 neurophysiology	 have	 not	 been	 able	 to	 clearly	 distinguish	 between	 motor	 and	 cognitive	
fatigue,	and	rarely	differentiate	fatigue	from	fatigability.	It	also	remains	unclear	whether	systemic	
and	 central	 inflammation	 drives	 MS	 fatigue.	 The	 following	 definition	 of	 fatigue	 was	 recently	
proposed:	 “The	 decrease	 in	 physical	 and/or	 mental	 performance	 that	 results	 from	 changes	 in	
central,	psychological,	and/or	peripheral	factors”	30.		
We	aimed	to	validate	the	Fatigue	Scale	for	Motor	and	Cognitive	Functions	(FSMC),15	a	frequently	
used	 fatigue	 scale	 among	 MS	 patients	 in	 Denmark,	 and	 to	 compare	 it	 with	 the	 already	 well-
established	Modified	Fatigue	Impact	Scale	(MFIS)	(1998).	
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Cognition	in	MS:	self-reported	and	objective	measures	
	
Cognitive	 impairment	 (CI)	 is	 frequent	 in	 people	 with	 MS.	 CI	 in	 MS	 patients	 typically	 affects	
memory,	information	processing	speed,	learning,	and	executive	function,	thus	influences	activities	
of	 daily	 living	 (ADL)	 and	QoL31,	32.	 CI	 is	 the	primary	 cause	of	 unemployment	 in	 people	with	MS,	
being	 reported	 in	 seven	 to	 eight	 out	 of	 ten	 cases16,	31,	33.	 CI	 may	 progress	 as	 a	 sign	 of	 disease	
activity;	 its	monitoring	 is	 also	 important	when	 treating	 patients	with	 immunomodulatory	 drugs	
that	may	 induce	 progressive	multifocal	 leukoencephalopathy	 (PML).	 Cognitive	 screening	 is	 thus	
valuable	both	as	a	means	of	assessment	and	as	a	guide	for	treatment34,	35.	Prevalence	studies	have	
found	cognitive	impairment	in	approximately	50%	of	those	afflicted	by	MS,	based	on	performance	
below	a	chosen	threshold	(usually	1.5	SDs	below	average).	Typically	cross-sectional,	such	studies	
do	not	reflect	long-term	outcome32.	However,	patients	with	high	premorbid	cognitive	reserve	may	
not	 cross	 the	 threshold	 into	 impairment,	 despite	 the	 notable	 decline	 from	 previous	 function36.	
Given	the	prevalence	and	morbidity,	there	is	a	need	for	cost-effective	screening	tools	for	cognitive	
impairment	that	can	longitudinally	evaluate	cognitive	decline.		
The	Multiple	Sclerosis	Neuropsychological	Screening	Questionnaire	(MSNQ)	 is	a	PRO	that	can	be	
easily	administered	by	either	the	patient	(MSNQ-P)	or	an	informant	(MSNQ-I).	It	has	been	shown	
to	have	an	acceptable	reproducibility	and	to	provide	valid	assessment	of	cognitive	dysfunction	in	
American,	Argentinean,	and	Dutch	populations.37-40	
The	objective	of	our	study	was	to	validate	a	Danish	translation	of	the	MSNQ,	compared	to	formal	
neuropsychological	testing	as	well	as	to	the	Symbol	Digit	Modalities	Test	(SDMT),	and	to	test	for	
construct	validity	with	depression	(BDI),	and	disability	(EDSS/MSIS).	
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Symbol	Digit	Modalities	Test	(SDMT)	
Cognitive	 impairment	 occurs	 even	 in	 the	 earliest	 stages	 of	 the	 disease,	 irrespective	 of	 disease	
duration.	Cognitive	deficits	may	develop	 independently	 from	physical	disability,	even	 in	cases	of	
benign	MS.	There	are	reports	of	relapse	with	primary	cognitive	 impairment.31,	41-43	Nevertheless,	
cognitive	disturbances	have	also	been	shown	to	correlate	with		functional	status	measured	by	the	
Expanded	Disability	Status	Scale	(EDSS),	and	the	presence	of	cognitive	decline	may	predict	a	more	
progressive	disease	course42,	44,	45.	Different	aspects	of	general	 cognitive	 functioning	may	 impact	
intellectual	disability,	including	information	processing	efficiency,	verbal	and	visuospatial	memory,	
executive	 functioning,	 attention,	 and	 visual	 perceptual	 processing	 -	 for	 which	 dedicated	
neuropsychological	test	batteries	have	been	developed.	Particularly,	processing	speed	and	visual	
memory	seem	to	be	most	commonly	affected16,	32,	46.	
If	 only	 five	 minutes	 are	 available	 for	 testing,	 the	 SDMT	 test	 is	 recommended	 in	 the	 Brief	
International	 Cognitive	 Assessment	 for	MS	 (BICAMS)	 as	 the	 cognitive	 test	 of	 choice.	 This	 easily	
administered	 test	 measures	 processing	 speed	 and	 working	 memory,	 does	 not	 require	 trained	
personnel,47,	48	and	is	an	effective	tool	for	detecting	cognitive	decline	in	clinical	practice49.	
Using	the	SDMT	in	a	few	MS	cohorts,	natalizumab	treatment	has	been	shown	to	have	a	positive	
effect	on	cognition.	The	frequency	of	SDMT	testing	and	follow-up	varies	in	these	studies:	monthly,	
six-monthly,	and	annual	examinations	have	been	applied	from	48	weeks	to	up	to	2	years44,	50-53.	
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Patients	 treated	 with	 natalizumab	 for	 CI	 may	 present	 with	 cognitive	 worsening	 as	 the	 first	
symptom	of	PML	(a	known	adverse	event	 in	the	SDMT);	we	use	SDMT	at	our	clinic	 immediately	
before	the	monthly	natalizumab	infusions	as	a	rapid	screening	test	for	subclinical	PML	in	JC-virus	
infected	patients.54,	55	However,	a	potential	practice	effect	may	complicate	 the	 interpretation	of	
SDMT	results,	as	patients	who	use	the	same	SDMT	every	month	gain	familiarity	with	it.		
Our	study	 in	the	Thesis	aimed	to	examine	cognitive	performance	and	practice	effect	on	patients	
exposed	to	monthly	testing	with	SDMT	during	natalizumab	treatment	of	up	to	35	months.		
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A B S T R A C T
Background: Our objective was to validate the Danish translation of the Fatigue Scale for Motor and Cognitive
Functions (FSMC) in multiple sclerosis (MS) patients.
Materials and methods: A Danish MS cohort (n = 84) was matched and compared to the original German va-
lidation cohort (n = 309) and a healthy control cohort (n = 147). The Modiﬁed Fatigue Impact Scale (MFIS)
was used as reference scale and Becks Depression Inventory-Fast Screen (BDI-FS) and Expanded Disability Status
Scale (EDSS) for confounding factors. We assessed internal consistencies; convergent, divergent, and predictive
validity; partial correlations correcting for depression; signiﬁcant diﬀerences between the mean scores of the
cohorts; and sensitivity and speciﬁcity with receiver operating characteristic (ROC) curves.
Results: Excellent internal consistencies for the total scale and subscales were found (α = 0.91–0.95). Strong
positive correlations between the two fatigue scales implied high convergent validity (total scores: r = 0.851,
p< 0.01). The two cohorts corresponded well when divided into subgroups (EDSS score; age; gender).
Correcting for depression did not result in any signiﬁcant adjustments of the correlations. The area under the
curve (AUC) for the ROC curves represented excellent accuracy (Danish MS cohort, AUC = 0.9190; German MS
cohort, AUC = 0.9034).
Conclusion: The Danish translation of the FSMC has a high convergent validity with another measure of fatigue
as well as excellent internal consistency and accuracy. It is found to be an applicable and recommendable
measure of fatigue in Danish MS patients.
1. Introduction
Multiple sclerosis (MS) is a disease characterised by numerous
neurological deﬁcits including sensory and motor problems. Fatigue is
the most commonly reported subjective symptom (65–95%), and often
found to be the most debilitating (40%) (Bakshi, 2003; Minden et al.,
2006). Together with depression, fatigue have a higher negative impact
on quality of life (QoL) than physical complaints like spasticity and
weakness (Amato et al., 2001). Fatigue in MS patients diﬀers from
normal tiredness experienced by healthy individuals. It is more severe,
disabling, and more likely to interfere with them meeting their re-
sponsibilities (Krupp et al., 1988). Not only is the symptom itself a great
burden to the patients, but the treatment of fatigue also presents a
challenge. A major challenge in dealing with fatigue is that the
aetiology and pathophysiology behind the symptom remains unclear
(Rottoli et al., 2016) and there is no common uniﬁed deﬁnition among
researchers and clinicians. A recently published study tried to limit this
problem of inconsistency, by proposing the following deﬁnition for
fatigue: “The decrease in physical and/or mental performance that results
from changes in central, psychological, and/or peripheral factors” (Rudroﬀ
et al., 2016).
Monitoring fatigue as a symptom in clinical practice is based on the
patient's own perception, and is most frequently done through self-re-
port questionnaires. Due to both cultural and linguistic diﬀerences
among countries, it is important to both translate and validate ques-
tionnaires in the native language of a patient population. Even though a
number of diﬀerent fatigue scales has been presented, most are only
validated in English. In this study we wanted to validate a frequently
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used fatigue scale among MS patients in Denmark, namely the Fatigue
Scale for Motor and Cognitive Functions (FSMC) (Penner et al., 2009),
and compare with the already well-established Modiﬁed Fatigue Impact
Scale (MFIS) (1998). Both scales provide the possibility to subdivide the
symptoms into the two entities of motor and cognitive fatigue.
2. Material &methods
2.1. Ethics
All procedures were performed according to the Declaration of
Helsinki and with permission from the Regional Committees on Health
Research Ethics for Southern Denmark (Reference number: S-
20140034). The study was also approved by Danish Data Protection
Agency (Reference number: 14/8330).
2.2. Participants
The study populations consisted of a Danish MS cohort (n = 84), a
German MS cohort (n = 309), and a German healthy controls cohort (n
= 147).
The Danish patient group was recruited, after written and oral in-
formed consent, from the MS clinic at Odense University Hospital in
2014.
Inclusion criteria were: i) Clinically deﬁnite MS diagnosed by a
specialist in Neurology according to the revised 2010 McDonald criteria
(Polman et al., 2011), ii) age> 18 years, and iii) Danish as native
language.
Exclusion criteria were: i) Other neurological diseases, ii) history of
developmental disorders or other learning disability, iii) previous or
present psychiatric diagnosis that is unlikely to be part of the patients’
MS, iv) alcohol or drug abuse, and v) corticosteroids treatment within
the last 4 weeks before evaluation. Information on age, gender, and
Expanded Disability Status Scale (EDSS) (Kurtzke, 2015) score were
also gathered.
All Danish study subjects completed the FSMC, the MFIS, and the
Becks Depression Inventory-Fast Screen (BDI-FS) during a visit to the
MS clinic.
2.3. Scales
All scales are self-evaluation questionnaires constructed as Likert
scales, with 1–5 points per item for the FSMC, 0–4 points per item for
the MFIS, and 0–3 points per item for the BDI-FS.
The FSMC consists of 20 items, with a subdivision of 10 motor and
10 cognition focused items. Cut-oﬀ values for grading of fatigue were
based on the original validation data (Penner et al., 2009). A score of≥
43 equals mild,≥ 53 equals moderate, and≥ 63 equals severe fatigue.
The total possible score ranges from 20 to 100 points. Cut-oﬀ values for
the cognitive subscale were ≥ 22 for mild, ≥ 28 for moderate, and ≥
34 for severe cognitive fatigue. For the motor subscale: ≥ 22 for mild,
≥ 27 for moderate, and ≥ 32 for severe motor fatigue (Penner et al.,
2009).
The MFIS consists of 21 items, where 9 are related to motor, 10 to
cognition, and 2 to psychosocial aspects of fatigue. The cut-oﬀ value
deﬁning fatigue related to MS is 38 points (Flachenecker et al., 2002),
and the total possible score is between 0 and 84 points.
For assessment of depression we used BDI-FS. The scale consists of 7
items and cut-oﬀ values for interpretation are provided, where 0–4
points equals minimal depression, 4–8 equals mild, 9–12 equals mod-
erate, and 10–21 equals severe (Smarr and Keefer, 2011).
2.4. Statistical analysis
Statistical validation was based on the recommendations of Bland
and Altman (Bland and Altman, 2002).
Descriptive statistics were calculated for mean age, gender dis-
tribution, and mean EDSS score. The distribution of fatigue severity was
calculated for each of the cohorts.
Due to the large sample size, manual inspection of box plots was
performed to evaluate Gaussian distribution. Based on this, the data did
not deviate from a normal distribution, and parametric tests were ap-
plied.
Cronbach's alpha was used for calculating internal consistency.
Good consistency was deﬁned as α ≥ 0.8.
Validity of the content was based on calculations on convergent and
divergent validity. For convergent validity, we performed bivariate
correlation analyses between the FSMC and the MFIS, both total and
subscales. Divergent validity was assessed through correlations be-
tween fatigue scales and i) BDI-FS and ii) EDSS scores. Pearson corre-
lation coeﬃcient was used to calculate the correlations between the
FSMC and MFIS. The correlations between the fatigue scales and the
BDI-FS and EDSS score was calculated by the same method, as well as
partial correlations correcting for the possible confounding eﬀect of
depression.
Predictive validity was calculated by comparing the cohorts through
unpaired t-tests. First, we divided the patients into subgroups based on
i) EDSS score (≤ 3 points for mild disability; 3.5–6 points for moderate
disability;≥ 6.5 points for severe disability), ii) age (10 year-intervals),
and iii) gender. Next, we compared matched subgroups from the two
MS cohorts and calculated the statistical signiﬁcance.
The statistical signiﬁcance of mean scores of individual items and of
the total sums in both scales were estimated using two-sampled t-tests
with unequal variances and post-hoc Bonferroni correction (for FSMC:
p<0.0025; for FSMC total and subscales: p< 0.0167; for MFIS:
p< 0.0024; for MFIS total and subscales: p< 0.0125).
Moreover, we calculated the sensitivity and speciﬁcity for diﬀerent
cut-oﬀ values of the FSMC using MFIS as reference variable. Receiver
operating characteristic (ROC) curves were plotted for these numbers.
The statistical analysis was done using STATA 14.0 and GraphPad
PRISM 7. All p-values< 0.05 were considered statistically signiﬁcant.
3. Results
3.1. Demographics
The study cohorts were well-matched in age, gender distribution,
and mean EDSS score (Table 1). Even though the Danish cohort (n =
84) was smaller than the German (n = 309), they had a similar dis-
tribution when subdividing into the diﬀerent fatigue severities ac-
cording to the cut-oﬀ values (Table 1).
3.2. Reliability of the FSMC
Internal consistency of the whole questionnaire was calculated and
compared to the original validation paper (Penner et al., 2009). In the
Danish patient group; α = 0.95 for the total scale, α = 0.93 for the
cognitive subscale, and α = 0.91 for the motor subscale. None of the
Cronbach's alpha values with missing item showed a higher value, in-
dicating that removing any of the questions, would not increase the
internal consistency of the questionnaire.
3.3. Validity of the FSMC
The two fatigue scales and related subscales correlated well. The
cognitive subscales (r = 0.8521, p< 0.0001) as well as the motor
subscales (r = 0.774, p<0.0001) had strong positive correlation
coeﬃcients, concluding with a high convergent validity (Table 2).
Except from the cognitive subscales, all scales including subscales
showed slightly weak, but signiﬁcant, correlations with depression
through the BDI-FS score (Table 3). Disability measured by EDSS scores
showed the same trend; however, with a somewhat stronger correlation
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with the motor subscale of the MFIS (r = 0.5291, p< 0.0001)
(Table 3). Partial correlations for depression did not result in any sig-
niﬁcant adjustments in the correlations (Table 3). No signiﬁcant cor-
relations were found with age or gender.
When considering predictive validity, the most severely disabled
patients (EDSS≥ 6.5) reported a higher fatigability in motor functions
(Table 4). However, they did not report higher cognitive fatigability
than less disabled patients, rather lower than patients with EDSS score
3.5–6. When comparing the Danish with the German MS cohort, there
was only one signiﬁcantly diﬀerent mean score between EDSS groups
(MFIS cognitive subscale, EDSS 3.5–6, p = 0.0117). The rest of the
subgroups matched well with their corresponding group (Table 4).
When subdividing based on gender, we found two signiﬁcant dif-
ferences between the two cohorts (FSMC motor subscale, female, p =
0.0225; MFIS cognitive subscale, female, p = 0.0331). No signiﬁcant
diﬀerences were found between the age groups, though we did not
analyse the youngest (20–29 years; Danish cohort, n = 0; German co-
hort, n = 30) and the oldest (≥ 70 years; Danish cohort, n = 4;
German cohort, n = 0) groups, due to low numbers (Table 4).
When performing multiple t-tests based on mean scores of single
items and total scores, we found no items in the FSMC and only 3 out of
21 items in the MFIS to be signiﬁcantly diﬀerent (Fig. 1).
3.4. Sensitivity and speciﬁcity
Based on the cut-oﬀ value for mild fatigue (43 points) (Penner et al.,
2009), the sensitivity was 100% and the speciﬁcity was 36%. With a
cut-oﬀ of 53 points (moderate fatigue), the sensitivity was decreased to
98% whereas the speciﬁcity was increased to 61%. Finally, with a cut-
oﬀ of 63 points (severe fatigue), the sensitivity further decreased to
84%, but the speciﬁcity was increased to 86%. Virtually equivalent
numbers for the respective cut-oﬀ values were found when analysing
the German MS cohort as well. Plotting of ROC curves for the Danish
cohort resulted in an area under the curve (AUC) of 0.9190 (95% CI:
0.85156–0.98645), whereas the corresponding number in the German
cohort was AUC= 0.9034 (95% CI: 0.86930–0.93752), representing an
excellent accuracy (deﬁned as> 0.9) of the test (Fig. 2).
4. Discussion
Validation of questionnaires in the native language of a given pa-
tient population is important due to possible cultural and linguistic
diﬀerences. The present study validated the FSMC in a Danish MS co-
hort and compared it to the already well-accepted MFIS and the
German study cohorts from the original validation of the scale (Penner
et al., 2009).
The two MS cohorts were well-matched in terms of gender and EDSS
Table 1
Demographics of the study cohorts.
Danish cohort German cohort Healthy controls
N 84 309 147
Mean age (SD) 51.1 (9.4) 43.4 (9.9) 41.7 (12.9)
Gender
– Female, N (%) 58 (69) 206 (67) 92 (63)
– Male, N (%) 26 (31) 103 (33) 55 (37)
EDSS (SD) 3.43 (1.8) 3.68 (1.2) –
Degree of fatigue
– Mild, N (%) 11 (9.5) 48 (15.5) 13 (8.8)
– Moderate, N (%) 15 (17.9) 59 (19.1) 6 (4.1)
– Severe, N (%) 51 (60.7) 153 (49.5) 2 (1.4)
Note: N, number of subjects; SD, standard deviation; %, percentages.
Table 2
Correlations between the fatigue scales in the Danish cohort.
FSMC_M MFIS_C MFIS_M MFIS_PS MFIS_T
FSMC_C 0.7469** 0.8521** 0.5364** 0.6565* 0.7779**
FSMC_M 0.6669** 0.774** 0.7532** 0.8138**
FSMC_T 0.8154** 0.6975** 0.7527** 0.851**
Note: Pearson correlation, 2-tailed, FSMC, Fatigue Scale for Motor and Cognitive
Functions; MFIS, Modiﬁed Fatigue Impact Scale; _C, cognitive subscale; _M, motor sub-
scale; _PS, psychosocial subscale; _T, total score of the scale.
** p< .01.
Table 3
Correlations and partial correlations controlling for depression shown in parentheses
between fatigue scales and confounding factors in the Danish cohort.
BDI-FS EDSS
FSMC_C 0.1854 0.0581 (0.0469)
FSMC_M 0.3125** 0.3526** (0.3504**)
FSMC_T 0.2645* 0.2153* (0.2057)
MFIS_C 0.2054 0.07032 (0.0582)
MFIS_M 0.2857** 0.5291** (0.5338**)
MFIS_PS 0.3303** 0.2927** (0.2878**)
MFIS_T 0.286** 0.3341** (0.3298**)
Note: Pearson correlation, 2-tailed, FSMC, Fatigue Scale for Motor and Cognitive
Functions; MFIS, Modiﬁed Fatigue Impact Scale; _C, cognitive subscale; _M, motor sub-
scale; _PS, psychosocial subscale, _T, total score of the scale; BDI-FS, Becks Depression
Inventory-Fast Screen; EDSS, Expanded Disability Status Scale.
* p< .05.
** p< .01.
Table 4
Mean scores with standard deviations of the Danish cohort based on subgroups.
FSMC_C FSMC_M FSMC_T MFIS_C MFIS_M MFIS_PS MFIS_T
EDSS
0–3 31.12 (± 10.58) 31.86 (± 10.04) 62.98 (± 20.04) 17.90 (±8.62) 16.10 (± 7.65) 3.31 (± 2.02) 37.31 (± 17.09)
3.5–6 33.97 (± 8.48) 36.31 (± 7.93) 70.28 (± 14.54) 20.63 (±7.13) 21.10 (± 7.04) 3.66 (± 1.84) 45.38 (± 14.09)
≥ 6.5 28.90 (± 9.45) 38.10 (± 6.94) 67.00 (± 15.00) 16.00 (±7.27) 25.10 (± 5.86) 4.30 (± 1.42) 45.40 (± 11.46)
Age
20–29 – – – – – – –
30–39 29.40 (± 9.94) 33.20 (± 12.66) 62.60 (± 22.07) 14.80 (±8.44) 17.00 (± 9.37) 3.40 (± 2.41) 35.20 (± 18.95)
40–49 30.52 (± 10.25) 32.59 (± 9.85) 63.10 (± 18.87) 17.66 (±8.59) 17.86 (± 8.94) 3.55 (± 2.08) 39.07 (± 16.97)
50–59 34.55 (± 9.15) 36.58 (± 6.84) 71.13 (± 14.78) 20.94 (±7.04) 21.26 (± 5.76) 3.71 (± 1.64) 45.90 (± 12.55)
60–69 30.30 (± 9.50) 31.70 (± 9.01) 62.00 (± 16.27) 18.00 (±5.85) 16.80 (± 8.04) 2.70 (± 1.57) 37.50 (± 14.05)
≥ 70 32.50 (± 10.91) 38.25 (± 10.90) 62.00 (± 21.05) 20.75 (±12.31) 21.75 (± 8.02) 5.00 (± 1.41) 47.50 (± 21.67)
Gender
Female 33.02 (± 20.50) 34.71 (± 28.80) 67.72 (± 32.13) 19.40 (±7.48) 19.48 (± 7.00) 3.72 (± 1.81) 42.60 (± 13.96)
Male 29.54 (± 9.36) 33.38 (± 9.38) 62.92 (± 17.41) 17.19 (±9.03) 18.15 (± 9.56) 3.19 (± 2.06) 38.54 (± 19.26)
Note: FSMC, Fatigue Scale for Motor and Cognitive Functions; MFIS, Modiﬁed Fatigue Impact Scale; _C, cognitive subscale; _M, motor subscale; _PS, psychosocial subscale; _T, total score
of the scale; EDSS, Expanded Disability Status Scale.
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score, except from a light skew of the Danish cohort towards more se-
verely disabled. This incoherence is likely due to the Danish patient
cohort on average being 10 years older, corresponding to a probable
longer disease duration.
Excellent internal consistencies were found, identical to the ones
found in the original validation (Penner et al., 2009), expressing high
interrelatedness of the items and/or a homogeneity of the whole scale
and subscales. However, the optimal value of alpha has been a point of
discussion in statistics, and some suggest that high values (> 0.90) may
indicate redundancies. (Tavakol, 2011).
Our results demonstrate a high convergent validity, with strong
positive correlations between the two fatigue scales and their subscales.
As expected, both motor subscales showed signiﬁcant correlations to
the EDSS score, though only at a weak to moderate level. There were no
correlations between the cognitive subscales and the BDI-FS score.
Neither did any of the fatigue scales or subscales correlate with age or
gender.
Interestingly, the most severely disabled patients (EDSS>6.5), had
a lower score on the cognitive subscale compared with those less dis-
abled. Likely, this is due to a smaller sample size in these patients. Two
signiﬁcant diﬀerences were found in the gender group and one found in
the EDSS group. This may be a result of the known statistical problem of
multiple testing and false positives (type I error). The same type of error
may apply to the comparisons of mean values between cohorts, as some
questions in the MFIS are signiﬁcantly diﬀerent. However, this may as
well suggest a better ﬁt of the FSMC to the Danish MS population than
the MFIS.
The calculated sensitivity and speciﬁcity showed the optimal results
for the cut-oﬀ values 53 and 63 points, depending on whether you
choose to accept a very high sensitivity on the expense of a moderate
Fig. 1. A comparison of single questions and total scores with standard deviations (SD). Note: Mean values of each item and the total scales and subscales with standard deviations of the
Danish (n = 84) and the German (n = 309) cohort; *signiﬁcant after post-hoc Bonferroni correction; FSMC, Fatigue Scale for Motor and Cognitive Functions; MFIS, Modiﬁed Fatigue
Impact Scale; _C, cognitive subscale; _M, motor subscale; _PS, psychosocial subscale; _T, total score of the scale. Each item is expressed with the name of the scale followed by the number
of the item and a letter referring to m: motor, c: cognition, or ps: psychosocial. Figure A: FSMC, single items; ﬁgure B: FSMC, total scores; ﬁgure C: MFIS, single items; ﬁgure D: MFIS, total
scores.
Fig. 2. Receiver operating characteristic (ROC) curves. Note: ROC curves for the total scale of the Fatigue Scale for Motor and Cognitive Functions (FSMC) plotted separately for the
Danish (A) and the German (B) cohorts using the Modiﬁed Fatigue Impact Scale (MFIS) as a reference variable.
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speciﬁcity or a decently high sensitivity and speciﬁcity, respectively.
We chose the listed cut-oﬀs based on maximal sensitivity and very low
speciﬁcity in the ﬁrst value (43 points) and decreasing sensitivity in the
last (63 points). When comparing the sensitivity and speciﬁcity calcu-
lated for the diﬀerent cut-oﬀ values in the Danish and German cohorts,
the numbers were virtually equal, suggesting application of the original
cut-oﬀ values for Danish patients. The accuracy of the test measured by
the area under the curve is excellent, representing high reliability in
terms of separating the cohort being tested into those with and those
without fatigue (Hajian-Tilaki, 2013). A possible bias lies in the relia-
bility of the MFIS to distinguish the presence of the symptom.
There are some limitations to our study. First, we had no healthy
Danish control group. Second, we were not able to check for test-retest
reliability. Third, the MFIS is not validated in Denmark. Future studies
may consider validating this scale in Denmark.
In conclusion, the FSMC has a high convergent validity with another
measure of fatigue as well as excellent internal consistency and accu-
racy. It is found to be an applicable and recommendable measure of
fatigue in Danish MS patients.
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Cognitive impairment is a common problem in multiple sclerosis (MS), occurring in approxi-mately 50% of patients. It typically involves 
memory, information-processing speed, learning, and 
executive function and, thereby, affects activities of daily 
living and quality of life.1,2 Moreover, cognitive impair-
ment is often the primary cause of unemployment, 
reported in 70% to 80% of all patients with MS.1,3,4 
Cognitive impairment may prove to be the only param-
eter in a few patients with MS and especially in patients 
with MS treated with immunomodulatory drugs that 
can induce progressive multifocal leukoencephalopa-
thy. Cognitive screening is, thus, incredibly valuable as 
a means of assessment and as a guide for treatment.5,6 
Considering the prevalence and morbidity, there is 
a need for cost-effective screening tools for cognitive 
impairment in MS.
The best-validated fast screening test in patients with 
MS is the Symbol Digit Modalities Test (SDMT). This 
test is easy to administer and correlates well with cogni-
tive impairment as measured by other standardized neu-
ropsychological batteries assessing multiple functions 
and brain atrophy.7 The SDMT, however, addresses 
only a fraction of the cognitive functions, such as pro-
cess speed and visuospatial and working memory.8,9
The Multiple Sclerosis Neuropsychological Screen-
ing Questionnaire (MSNQ) is a brief patient-reported 
outcome scale by either the patient (MSNQ-P) or the 
informant (MSNQ-I) and is easy to administer. It has 
previously been shown to have acceptable reproducibil-
ity and to provide valid assessment of cognitive dysfunc-
tion in American, Argentinean, and Dutch populations. 
In contrast to the SDMT, the MSNQ can provide 
information about self- and informant-perceived cogni-
tive dysfunction.10-13
The objective of this study was to validate a Danish 
translation of the MSNQ compared with formal neuro-
psychological testing and with the SDMT and measures 
of depression and disability.
Methods
Ethics
All the procedures were performed according to the 
Declaration of Helsinki and with permission from the 
Danish Data Protection Agency (14/8330).
Translation of MSNQ
The MSNQ was translated by a bilingual translator 
from English to Danish and then was translated from 
Danish to English by another translator to correct for 
any linguistic corrections or oversights.
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(patients >60 years old) or incomplete neuropsychologi-
cal testing. Three informants did not return the MSNQ-
I (Figure 1). Statistical analyses were performed using 
GraphPad PRISM 7 (GraphPad Software Inc, La Jolla, 
CA). Because data were not distributed normally, non-
parametric statistics were used.
Results
Demographics and Comparison of Subgroups
Comparing patients who underwent neuropsycho-
logical testing (n = 77) with those who did not (n = 49), 
we found no differences in demographics in relation to 
age, disease duration, and disability as measured by the 
EDSS and the MSIS. There were also more men in the 
neuropsychological group (43%) compared with in the 
group that was not tested by a neuropsychologist (26%) 
(P < .05) (Table 1).
Test-Retest of MSNQ-P and Correlation 
Between MSNQ-I and MSNQ-P
The squared test-retest correlation of the MSNQ-P 
was R2 = 0.79 (P < .0001) (Figure 2A) and the squared 
correlation of the informants (MSNQ-I) and patients 
(MSNQ-P) was low but significant (R2 = 0.22, P < 
.0001) (Figure 2B).
Squared Correlation Between MSNQ and 
Neuropsychological Tests and BDI
When correlating the MSNQ-I or the MSNQ-P 
(greater than the cutoff score of 26 points) with the z 
Study Population
We studied 126 patients diagnosed as having MS in 
the Department of Neurology, Odense University Hos-
pital (Odense, Denmark), over 7 consecutive years (Jan-
uary 1, 2000, through December 31, 2006). The inclu-
sion criteria were 1) a diagnosis of MS according to the 
McDonald criteria,14 2) an informant with face-to-face 
contact with the patient three or more times a week, 3) 
age older than 18 years, 4) Danish as the first language, 
and 5) informed consent. The exclusion criteria were 
1) neurologic deficits not related to MS, 2) a history of 
developmental disorders or other learning disabilities, 
3) previous or present psychiatric disease that is unlikely 
to be part of the patient’s MS, 4) alcohol or drug abuse, 
and 5) corticosteroid treatment in the 4 weeks before 
evaluation. Informants were selected by the following 
criteria: closest family or friend with whom the patient 
lives or has at least three weekly contacts, in the follow-
ing prioritized rank: spouse, father/mother, daughter/
son, friend/closest family.
Application of MSNQ, SDMT, and 
Neuropsychological Testing
Patients and their respective informants were carefully 
given standardized instructions on how to fill out the 
MSNQ10 and the Beck Depression Inventory (BDI)15 
during each contact. Patients completed questionnaires 
in the department, and a neurologist (M.B. or T.S.) 
assessed clinical deficits by means of the MS Impairment 
Scale (MSIS),16,17 the Expanded Disability Status Scale 
(EDSS),18 and the SDMT.19,20
Informants completed the MSNQ-I during the visit 
or within a few weeks. The first 77 patients examined 
were chosen for neuropsychological testing, which 
occurred a few weeks after contact with the neurolo-
gist. The test battery comprised the following tests: the 
Rey Auditory Verbal Learning Test, the Trail Making 
Test B, the Wisconsin Card Sorting Test, the Boston 
Naming Test, and Digit-Symbol Coding. A z score of 
the combined neuropsychological tests was calculated 
from the test results, and a z score less than –1.5 SD 
was used as the cutoff point to diagnose true cognitive 
impairment.
Based on earlier studies, a cutoff score of 26 points or 
greater on the MSNQ-I and the MSNQ-P was chosen 
as a sign of cognitive impairment.10,12,13,21,22 Forty-four 
patients were retested (Figure 1) to investigate the test-
retest variability of the MSNQ-I and the MSNQ-P.
Statistical Methods
Z scores were based on sex- and age-matched con-
trols. Z scores could not be calculated for nine patients 
due to either missing age-matched normal values 
Figure 1. Study flowchart
A total of 126 patients with multiple sclerosis (MS) were includ-
ed in the study, and 77 of these underwent formal neuropsy-
chological testing. Data from nine patients were incomplete due 
to failure to complete the neuropsychological test battery. More-
over, three informants did not return Multiple Sclerosis Neuro-
psychological Screening Questionnaire–Informant (MSNQ-I). All 
included patients were assessed for disability using Expanded 
Disability Status Scale (EDSS) and Multiple Sclerosis Impair-
ment Scale (MSIS) and performed Symbol Digit Modalities Test 
(SDMT). A total of 44 patients were retested with MNSQ-Patient 
(MNSQ-P) to determine test-retest reliability.
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Correlation of SDMT and Neuropsychological 
Testing
As a positive control for bedside neuropsychological 
testing in patients with MS, we also tested the squared 
correlation between the well-established SDMT and the 
total neuropsychological test panel. As expected, this 
squared correlation was highly significant (R2 = 0.68, P 
< .0001) (Figure 4). When correlated to the individual 
neuropsychological tests, we found the best squared cor-
relations to Digit-Symbol Coding and the Trail Making 
Test B. The SDMT also correlated to the Rey Auditory 
Verbal Learning Test and the Wisconsin Card Sorting 
Test but not to the Boston Naming Test (Table 2).
Discussion
The results of the present study show that a Dan-
ish translation of the MSNQ, despite good test-retest 
reliability, has no statistically significant correlation to 
cognitive impairment found on standard neuropsycho-
logical testing. This is in contrast to validation studies 
in other languages.12,13,21,22 When using the now well-
established SDMT scale, we did, however, find a highly 
significant correlation with the neuropsychological test 
battery, demonstrating the superiority of this scale in 
establishing the presence of cognitive impairment in 
MS.23-26 Several factors may explain the low sensitivity 
and specificity of the MSNQ in the present study. First, 
we used an MSNQ cutoff score greater than 26, which is 
the cutoff score used in the original validation.10 Other 
studies have used different cutoff values to achieve high-
er sensitivity and specificity, and the optimal cutoff score 
seems to change from study to study.13,22,27 Using other 
cutoff points did not increase the sensitivity or specificity 
in the present population.
Second, compared 
with most of the earlier 
MSNQ validation stud-
ies performed,13,22,27 the 
present cohort demon-
strated a shorter disease 
duration (mean, 7.8 
years), a lower EDSS 
s c o r e  ( m e a n ,  2 . 8 ) , 
and fewer cognitively 
impaired patients (13 of 
77). A screening tool for 
cognitive impairment 
should, however,  be 
relevant also in younger 
MS cohorts with shorter 
disease durations, and, 
when using the SDMT 
in the present cohort, we 
score of the complete neuropsychological test battery, 
we found no significant squared correlation with either 
scale (MSNQ-P: R2 = 0.0084, P = .457; MSNQ-I: R2 = 
0.0345, P = .1388) (Figure 3). Neither did the MSNQ-I 
and the MSNQ-P correlate with the individual neuro-
psychological tests (Table 2). We found low sensitiv-
ity and specificity of the MSNQ-P (21.4% and 76%, 
respectively) and the MSNQ-I (33% and 65.5%, respec-
tively). Both scales did, however, correlate to BDI scores 
(MSNQ-P: R2 = 0.25, P < .0001; MSNQ-I: R2 = 0.197, 
P < .0001 [data not shown]).
Squared Correlation Between MSNQ and 
Disability Scores
To investigate whether there is a correlation between 
cognitive dysfunction measured by the MSNQ and dis-
ability, we compared MSNQ-I with EDSS and MSIS 
scores. We found no squared correlation to either objec-
tive disability measure (EDSS: R2 = 0.0036, P = .5; 
MSIS: R2 = 0.0001, P = .89 [data not shown]).
Table 1. Baseline demographic characteristics 
of the 126 study participants
Neuropsychological testing
Characteristic Yes (n = 77) No (n = 49) P value
Age, mean (range), y 45.6 (26-71) 48.4 (28-68) .08
Sex, M:F, % 43:57 26:74 .03
Disease duration, mean 
(range), y
7.8 (4-10) 7.2 (4-10) .06
EDSS score, mean 
(range)
2.8 (0-7.0) 3.4 (1-8.0) .11
MSIS score, mean 
(range)
22.1 (0-86) 21.9 (0-103) .72
Abbreviations: EDSS, Expanded Disability Status Scale; MSIS, MS 
Impairment Scale.
Figure 2. Linear fit regression of Multiple Sclerosis Neuropsychological 
Screening Questionnaire–Patient (MSNQ-P) and MSNQ-Informant 
(MSNQ-I)
A, MSNQ-P scores for test-retest linear fit regression (n = 44). Each dot indicates the MSNQ-P score 
in the test-retest (variability within same patient). B, MSNQ-P/MSNQ-I linear fit regression (n = 116). 
Each dot indicates an MSNQ-P/MSNQ-I score (variability between patient and informant).
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data. We found that 
the MSNQ-I and the 
MSNQ-P correlated 
significantly with BDI 
scores. Other studies 
have also suggested that 
the MSNQ is influenced 
by psychosocial vari-
ables, such as anxiety, 
rather than by objective 
status.13,29,30 The impact 
of psychosocial variables 
could be the explanation 
for the subpopulation of 
patients who reported 
high impact on self-
experienced cognitive 
impairment but had normal results on standard neuro-
psychological testing.
An opposite subgroup with low MSNQ-I and 
MSNQ-P scores had severe cognitive impairment when 
tested with formal neuropsychological tests. This might 
be explained by a coping strategy of the patients and 
informants to undervalue cognitive impairment and, 
therefore, report low MSNQ-P and MSNQ-I scores in 
self-perceived cognitive impairment. Another explana-
tion for low MSNQ-P scores and high cognitive impair-
ment could also be that severely affected patients do not 
perceive the dementia. Further studies are needed to 
clarify these issues of self-assessed measures of cognition.
In conclusion, this study does not support use of the 
MSNQ-P or the MSNQ-I as a sensitive or valid screen-
did find very high sensitivity compared with neuropsy-
chological testing.
Sonder et al27 demonstrated lower loadings regarding 
how individual questions are weighted and affect the 
MSNQ score. Different study populations and cultural 
differences regarding the content of the questions should 
also be considered in future studies. Unfortunately, this 
study was not designed to test for such differences.
Finally, it should be considered whether the MSNQ 
actually does measure cognitive impairment. Strober et 
al28 recently reported that self-assessed measures of cog-
nition do not correlate with systematic neuropsychologi-
cal testing but rather with quality of life and behavioral 
Table 2. Correlations between MSNQ-P, 
MSNQ-I, and SDMT and individual 
neuropsychological tests
Measure
Neuropsychological tests
D-S/SS RAVLT TMT-B WCST BNT
MSNQ-P
  R2
  P value
0.000385
<.8663
0.00713
<.4651
0.01447
<.2974
0.010923
<.3689
0.002
<.6993
MSNQ-I
  R2
  P value
0.058501
<.0604
0.02064
<.2652
0.00327
<.6588
2.158e-6
<.9910
0.00085
<.8217
SDMT
  R2
  P value
0.6736
<.0001
0.2753
<.0001
0.4478
<.0001
0.1272
<.0016
0.0136
<.3113
Note: n = 77. Altogether, no correlations were found between 
MSNQ-P and MSNQ-I and neuropsychological tests. SDMT corre-
lated with D-S/SS, TMT-B, RAVLT, and WCST.
Abbreviations: BNT, Boston Naming Test; D-S/SS, Digit-Symbol 
Coding; MSNQ-P and MSNQ-I, Multiple Sclerosis Neuropsychologi-
cal Screening Questionnaire–Patient and –Informant, respectively; 
RAVLT, Rey Auditory Verbal Learning Test; SDMT, Symbol Digit 
Modalities Test; TMT-B, Trail Making Test B; WCST, Wisconsin Card 
Sorting Test.
Figure 4. Linear fit regression of Symbol 
Digit Modalities Test (SDMT) and 
neuropsychological test battery
Linear fit regression between SDMT scores and mean z scores of 
the neuropsychological tests for individual patients in standard 
deviations. We found a significant correlation with z scores and 
SDMT scores (R2 = 0.68, P < .0001) (n = 68). 
Figure 3. Linear fit regression of Multiple Sclerosis Neuropsychological 
Screening Questionnaire–Patient (MSNQ-P) or MSNQ-Informant 
(MSNQ-I) and neuropsychological test battery
Linear fit regressions between MSNQ-P (A) and MSNQ-I (B) scores and mean z scores of all the neuro-
psychological tests (n = 68). No correlation was found with z scores and MSNQ-P or MSNQ-I.
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ing tool for cognitive impairment in Danish patients 
with MS. In contrast, this study found the SDMT to be 
more reliable owing to higher sensitivity and specificity. 
Further studies are needed to assess the effect of differ-
ences in study populations, choice of cutoff values, and 
cultural and psychosocial impact. o
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PRACTICE POINTS
• We studied the validity and reliability of the 
Multiple Sclerosis Neuropsychological Screening 
Questionnaire (MSNQ), a screening tool for cog-
nitive impairment, in 126 Danish patients and 
their informants.
• Test-retest reliability of the MSNQ-Patient 
(MSNQ-P) was assessed on a subsample of 44 
patients and was found to be high. There was a 
high correlation between the MSNQ-P and the 
MSNQ-Informant (MSNQ-I).
• The Danish versions of the MSNQ-P and the 
MSNQ-I showed no correlation with formal 
neuropsychological testing. In contrast, they dem-
onstrated significant (albeit low) correlation with 
depression, suggesting correlation of the Danish 
MSNQ-P and MSNQ-I with behavioral outcomes 
rather than with neuropsychological measures.
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A B S T R A C T
Objectives: How practice eﬀect inﬂuences cognitive testing measured by monthly Symbol Digit Modalities Test
(SDMT) during natalizumab treatment, and what factors confound such eﬀect.
Methods: Eighty patients were examined monthly with SDMT for 26.2± 8.4 months. After 26.0 ± 8.1 months,
SDMT was also performed with a rearranged key in 59 cases. Results of SDMTs with the rearranged and
previous regular key were compared. We examined if gender, age, Extended Disability Status Scale (EDSS),
relapses, and disability progression/improvement inﬂuence SDMT performed with the regular and the
rearranged key, respectively. We also explored if natalizumab applied before regular monthly SDMT may
inﬂuence practice eﬀect and cognition.
Results: SDMT performance improved by 1.2 points/test during the ﬁrst six months and by 0.4 points/test
thereafter. Rearranging the symbols of the key after 26.0 ± 8.1 months returned SDMT scores to baseline
indicating a practice eﬀect. Such practice eﬀect was more signiﬁcant after longer testing period, but was not
inﬂuenced by gender, age, relapses, disability progression and prior natalizumab treatment. Although the
change from baseline to 2.5 years was signiﬁcant in subgroups with EDSS 0–3, 3.5–5.5 and 6–7.5, this was
higher in patients with EDSS 0–3 compared to 6–7.5.
Conclusions: Practice eﬀect signiﬁcantly contributes to continuous improvement in SDMT performance during
natalizumab treatment: to test cognition, a change in key is required. Practice eﬀect is less pronounced in
patients with advanced disease. Cognition remains stable even in patients with progressive disease during more
than 2 years of natalizumab treatment indicated by scores corresponding to baseline after changing the key.
1. Introduction
The estimated prevalence of cognitive impairment in MS ranges
between 43–70% (Benedict et al., 2006; Rao et al., 1991) both in the
early and late stages of the disease. The eﬀect of cognitive impairment
on everyday life activities, employment status, and social relationships
is prominent (Amato et al., 1995; Banati et al., 2010). Cognitive
impairment can occur irrespective of disease duration even in the
earliest stages of the disease (Achiron and Barak, 2003; Banati et al.,
2010; Glanz et al., 2007) i.e. clinically isolated syndrome (CIS)(Achiron
and Barak, 2003; Feuillet et al., 2007; Glanz et al., 2007). Cognitive
deﬁcits may develop independently from physical disability and in
patients with benign MS (Feuillet et al., 2007; Glanz et al., 2007;
Portaccio et al., 2009). Nevertheless, cognitive disturbances have also
been shown to correlate with high EDSS scores, and the presence of
cognitive decline may predict a more progressive disease course
(Banati et al., 2010; Portaccio et al., 2009; Zipoli et al., 2010).
Intellectual disability of MS aﬀects various aspects of general
cognitive functioning, including eﬃciency of information processing,
verbal and visuo-spatial memory, executive functioning, attention, and
visual perceptual processing. all of which are detectable with sensitive
neuropsychological test batteries specially developed for the MS
population (Benedict et al., 2006; Rao, 1991). Particularly processing
speed and visual memory seem to be most commonly aﬀected
(Benedict et al., 2006; Rao et al., 1991).
The Symbol Digit Modalities Test (SDMT) measures processing
speed and working memory. This test is recommended in the Brief
International Cognitive Assessment for MS (BICAMS) as the cognitive
test of choice, when only 5 min of testing is available. SDMT is easy to
administer, it does not require trained personnel (Benedict et al., 2008;
Langdon et al., 2012), and is an eﬀective tool to detect cognitive decline
in clinical practice (Van Schependom et al., 2014).
The eﬀect of natalizumab treatment on cognition has been eval-
uated by SDMT in a few MS cohorts: these indicated improved
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cognition (Holmen et al., 2011; Iaﬀaldano et al., 2012; Kunkel et al.,
2015; Morrow et al., 2010; Portaccio et al., 2013). The frequency of
SDMT testing and follow-up varies in these studies: monthly, 6-
monthly, and annual examinations have been applied for 48 weeks
up to 2 years (Holmen et al., 2011; Iaﬀaldano et al., 2012; Kunkel et al.,
2015; Morrow et al., 2010; Portaccio et al., 2013). Since one of the
earliest symptoms of progressive multifocal leukoencephalopathy
(PML) associated with natalizumab treatment is subacute cognitive
decline, SDMT can also be an eﬃcient and rapid screening test for
subclinical PML in patients infected with JC-virus (Sorensen et al.,
2012) before monthly natalizumab infusions. However, potential
practice eﬀect may complicate interpretation of SDMT results, i.e.
patients using the same SDMT every month become familiar with the
test and gain practice.
In this study, therefore we examined cognitive performance with
monthly SDMT during natalizumab treatment up to 35 months. We
evaluated a possible practice eﬀect by a single change in the order of
symbols in SDMT after 26.0 ± 8.1 weeks. We also examined the eﬀect
of confounding factors, such as age, gender, disability progression,
functional status and natalizumab treatment prior regular introduction
of SDMT.
2. Materials and methods
2.1. Study population and design
Eighty patients were enrolled, who have been treated with natali-
zumab at the Department of Neurology, Odense University Hospital,
Denmark (Table 1). The study duration ranged from the implementa-
tion of SDMT in November 2011 to September 2014.
Regular SDMT were performed as part of the routine protocol for
natalizumab treatment in the region of Southern Denmark. Data were
retrospectively reviewed: 2356 individual SDMTs were performed in
the study period. The number of consecutive tests per patient varied
from 5 to 39, which corresponded to follow up from 4 to 35 months
(26.2± 8.4 months). Sixty patients (75%) completed 25 consecutive
SDMTs, indicating their participation in the study for at least two years.
Demographics are summarized in Table 1.
The study was approved by the Regional Scientiﬁc Committees for
Southern Denmark and the Danish Data Protection Agency.
2.2. Data collection
SDMT was performed every 4th week before natalizumab infusion.
Every test was done in 90 s. Trained nurses collected SDMT data. EDSS
scores were determined every six months. For all patients, who had
been already treated with natalizumab at the implementation of the
SDMT in November 2011, baseline EDSS was the latest performed
EDSS, which due to routine EDSS scoring, could at maximum be 6-
months old. In September 2014, all clinical and SDMT data were
retrieved from the hospital database and from the Danish Multiple
Sclerosis Database. Data were stratiﬁed according to EDSS, gender,
age, relapses and natalizumab treatment before the introduction of
SDMT testing. Only the ﬁrst 30 consecutive SDMTs were included for
further analyses. Three cohorts were established based on baseline
EDSS: ≤3, 3.5-5.5 and ≥6. Three equally sized groups were deﬁned
based on the age of the patients. Disability progression was deﬁned as
≥1 point increase of EDSS persisting for at least 6 months retro-
spectively analyzed at 2 years; improvement was deﬁned as ≥1 point
EDSS decrease after 2 years; stable disease was deﬁned if EDSS change
was & $2lt;1 point after 2 years.
2.3. Introduction of a new SDMT key
Nine symbols are paired with numbers in the SDMT test (key). A
deﬁnite sequence of symbols should be paired with the correct number
during a timed (90 s) examination. At the end of the study period in
September 2014, all patients still treated with natalizumab (59
patients) were examined with two SDMT, approximately one hour
apart with the same nine symbols, but the pairing of symbols and
numbers in the key was rearranged. The main sequence of 110 symbols
in the test remained the same. At that time point, the number of SDMT
testing in this cohort ranged from 8 to 38, with a mean number of
SDMT 29.3 ± 8.8.
2.4. Statistical analysis
Statistical analyses were performed using STATA/IC version 13.1
for Windows. The Shapiro-Wilks test for normality was used to ensure
legitimate use of parametric statistics. To determine an overall pattern
in the improvement of SDMT scores, the mean of every consecutive test
was plotted, and analyzed using linear regression.
3. Results
3.1. Long-term SDMT performance during natalizumab treatment
To evaluate the long-term SDMT performance, we compared the
mean score for each consecutive monthly SDMT. This revealed a clear
overall improvement, with an increase in mean raw score up to 30
months. This improvement was most rapid during the ﬁrst six months,
indicated by an approximate improvement of 1.2 point per SDMT.
Thereafter, a mean improvement of 0.4 point per SDMT was detected
(Fig. 1).
3.2. Examination of practice eﬀect by the introduction of a new key
The SDMT scores improved signiﬁcantly even after the 4th con-
secutive monthly test (p=0.009, n=80) and thereafter (Fig. 1). Since a
practice eﬀect due to the frequent SDMT can be responsible for such an
early and continuous improvement, we investigated the eﬀect of a
rearranged key. In September 2014, 59 patients were examined with a
novel key in the SDMT: the symbols were the same as baseline but the
order was changed within the key. At that time point, 23 patients were
followed for more than 34 months, 22 patients were followed for more
than two years, and 14 patients were followed for less than 2 years but
for at least 8 months (Fig. 2). Changing the key returned the scores to
baseline in all groups. This indicated that a practice eﬀect signiﬁcantly
contributed to the improved SDMT performance. Longer testing with
frequent SDMT resulted in a more signiﬁcant improvement (Fig. 2B).
EDSS had no eﬀect on this pattern, except in patients with EDSS≥6,
where changes with the new key were not signiﬁcant (Fig. 3).
We next investigated the eﬀect of several factors on performance
with monthly SDMT over 2 years, i.e. their inﬂuence on the practice
eﬀect and cognition.
Table 1
Study design and demographics.
Study design
Patients treated with natalizumab 80
Male gender 23 (29%)
Female gender 57 (71%)
Patients suﬀering a relapse during the study 32 (40%)
Patients treated with natalizumab before the study 50 (63%)
Number of natalizumab infusions before the study 38.4± 16.4
Mean number of SDMTs per patient 26± 7a
Mean age at ﬁrst SDMT (years) 41.0± 9.7
Mean baseline EDSS 3.3± 2.0
Mean EDSS change during follow up 0.12
Mean ± standard deviation is shown where applicable.
a Equals 104± 28 weeks follow up.
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3.3. The eﬀect of disease severity, disability progression and
improvement
To investigate relationship between disease severity, cognition, and
practice eﬀect, we stratiﬁed patients according to EDSS and created
three cohorts: EDSS 0–3, 3.5–5.5, and 6–7.5. Monthly SDMT perfor-
mance and eﬀect of changing the key were examined in these cohorts.
Signiﬁcant increase over 2 years in SDMT scores was detected in the
groups with the EDSS≤3 (p & $2lt;0.001) and EDSS 3.5-5.5 (p=0.001).
SDMT scores returned to baseline in these subgroups by using the
rearranged SDMT key (Fig. 3). In the group with EDSS 6–7.5, baseline
SDMT scores were signiﬁcantly lower (p & $2lt;0.001 versus EDSS 0–3,
and p=0.005 versus EDSS 3.5–5.5, respectively). In addition, the
change from baseline to 2-year SDMT was not signiﬁcant in this group
(Fig. 3B), but became signiﬁcant after 2.5 years (p=0.03). Nevertheless,
the net change of SDMT scores from baseline to 2.5 years was
signiﬁcantly higher in patients with EDSS 0–3 compared to patients
with EDSS 6–7.5 (22.68 ± 11.11 and 10.06 ± 5.97, p & $2lt;0.001).
Scores returned to baseline after changing the key even in the cohort
of EDSS 6–7.5 (Fig. 3A).
To examine the eﬀect of disability progression or improvement on
SDMT performance and learning ability, patients were also stratiﬁed
according to disability progression (≥1 point increase of EDSS in 2
years, n=19), improvement (≥1 point EDSS decrease in 2 years, n=14)
or stable disease (change less than 1 EDSS point, n=46). A signiﬁcant
increase in SDMT scores during 2 years was observed in all three
cohorts (p=0.001, p=0.02 and p & $2lt;0.01 for stable, increased and
decreased EDSS, respectively). In addition, SDMT scores returned to
baseline in all three cohorts by using the rearranged SDMT key (data
not shown).
We also dichotomized the cohort based on a cut-oﬀ value below and
above 50 of the baseline SDMT, and examined the change of SDMT in
the two populations over two years. The mean change of SDMT in
patients with baseline SDMT 49 and below was 13.9, while in patients
with baseline SDMT 50 and over was 13.4 and this diﬀerence was not
signiﬁcant.
3.4. The eﬀect of age, relapse and gender
To investigate if age and disease activity inﬂuence cognitive
performance and practice eﬀect, we deﬁned three equally sized groups
based on age. There was no diﬀerence between the youngest and oldest
groups comparing SDMT scores at baseline and after 2 years (Fig. 4A).
The rate of increase in SDMT was also the same in the two groups
Fig. 1. Change in SDMT performance during 30 months of natalizumab treatment. SDMT was performed monthly during natalizumab treatment of 80 patients with MS.
Mean of monthly SDMT scores and 95% conﬁdence intervals are shown up to 31 consecutive SDMTS, i.e. 30 months.
Fig. 2. Practice eﬀect on SDMT performance. A. Mean of monthly SDMT scores are shown before introduction of regular monthly SDMT (baseline, white bar), and 2 years after
monthly SDMT (black bar). B. A new key was introduced by rearranging symbols. Patients were grouped according to the length of period with monthly SDMT at the time, when the new
key was introduced. White bars indicate baseline values, black bars indicate the latest performed SDMT, and grey bars show SDMT scores obtained with the new key. All bars indicate
mean.
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(Fig. 4B), and changing the key returned scores to baseline in both
groups (Fig. 4A).
Thirty-two patients (40%) experienced relapse during the study
period. This was not reﬂected in their SDMT results: no diﬀerence at
either baseline or after 2 years was observed comparing patients
suﬀering from at least one relapse and patients who did not have
relapses (Fig. 5A). Improved SDMT performance was detected in both
groups after 2 years, (p & $2lt;0.01, respectively) (Fig. 5A). Changing
the key returned scores to baseline in both groups (Fig. 5A).
Gender had no eﬀect on SDMT performance, and changing the key
similarly returned SDMT scores to baseline in male and female patients
(data not shown).
Fig. 3. Eﬀect of EDSS on SDMT scores. A. Patients were stratiﬁed into three groups based on EDSS: 0–3.0 (left panel), 3.5–5.5 (middle panel), and 6.0–7.5 (right panel). SDMT
scores and mean are shown in the three cohorts: before introduction of regular monthly SDMT (Baseline) to examine eﬀect of functional status on cognitive domains, 2 years after
monthly SDMT (Year 2) and after the introduction of a new key with rearranged symbols (New key) to examine the inﬂuence on practice eﬀect. B. Mean of monthly SDMT scores and
95% conﬁdence intervals are shown up to 31 consecutive SDMTS, i.e. 30 months within the subgroups of patients with EDSS: 0–3.0, 3.5–5.5 and 6.0–7.5.
Fig. 4. Eﬀect of age on SDMT scores. SDMT scores before introduction of regular monthly SDMT (Baseline) and 2 years after monthly SDMT (Year 2) are shown in the youngest
and oldest one-thirds of the cohort. A. SDMT scores in the youngest and oldest cohorts at baseline, year 2 and with the new key. B. Slope of increase in SDMT scores during 2 years are
shown in the youngest and oldest one-thirds of the cohort.
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3.5. The eﬀect of natalizumab treatment prior to regular SDMT
testing
We also considered that continuous increase in SDMT may also
reﬂect the eﬀect of natalizumab on cognition or even the practice eﬀect.
Therefore, we examined the eﬀect of prior natalizumab treatment on
the SDMT performance with the regular and the rearranged key.
Patients were stratiﬁed into two groups: natalizumab before monthly
SDMT, i.e. treatment before November 2011 and natalizumab started
together with regular SDMT. After 1 and 1.5 year of SDMT testing,
there was a signiﬁcant increase in SDMT in both groups, respectively
(year 1: pretreated p & $2lt;0.01 n=51, simultaneously treated p=0.03,
n=20; year 1.5: pretreated p & $2lt;0.01, n=50, simultaneously treated
p=0.05, n=17)(Figure 6). At 2 years, the change in SDMT remained
signiﬁcant in patients pretreated with natalizumab (p &
$2lt;0.01 n=48), but was not signiﬁcant in simultaneously treated
patients (p=0.09, n=12) (Fig. 5B). Changing the key returned SDMT
scores to baseline in both groups (Fig. 5B).
4. Discussion
In this study, we examined long-term changes in monthly SDMT
performance during natalizumab treatment. We observed a continuous
rise in scores up to 30 monthly SDMT over 2.5 years. The increase was
most apparent in the ﬁrst six months of SDMT testing, but mean scores
continued to increase by about 0.4 point per test thereafter. Similar
continuous increase was also observed in a study with shorter follow up
(48 weeks) of monthly testing, and the steepness of the slope also
declined over time (Morrow et al., 2010). Testing at every 6 months or
annual examination in other studies also resulted in signiﬁcant
improvement after 2 years (Holmen et al., 2011; Iaﬀaldano et al.,
2012).
We considered that such a change in the rate of increase could be
due to two reasons. First, it may be caused by a practice eﬀect, i.e.
patients using the same SDMT every month become familiar with the
test and gain practice. Second, the possible eﬀect of natalizumab
treatment on cognition may reach a plateau and only minor improve-
ments can be seen thereafter. Therefore, (i) we explored the eﬀect of a
new key on SDMT performance; (ii) we examined confounding factors
related to the disease, and (iii) we addressed the eﬀect of natalizumab
administered prior to the introduction of regular, monthly SDMT. A
previous paper examined the eﬀect of alternate versions of SDMT with
diﬀerent keys in healthy subjects (Benedict et al., 2012). In contrast,
here we performed a longitudinal study in MS patients, and (i)
examined the evolution of the learning eﬀect over two years, (ii)
veriﬁed the learning eﬀect by changing the key after two years, and (iii)
related the evolution of the learning eﬀect to demographic and clinical
characteristics.
We found that a simple change in the order of the symbols
completely reversed the increase in SDMT scores and returned it to
baseline values, indicating that practice eﬀect signiﬁcantly impact
SDMT results during natalizumab treatment if frequent testing is
applied. Longer testing period resulted in better improvement in
SDMT performance, which also supports the contribution of practice
eﬀect. Such practice eﬀect may be caused by memorization of test
stimuli or familiarity with the process itself. However, a single change
after more than 2-year frequent testing should not completely abrogate
the eﬀect, if only familiarity plays a role. Patients may also have
diﬃculty to adapt to a new key after repetitive usage of the same SDMT
version, and this might inﬂuence the outcome with the new key.
However, it is unlikely that this would be responsible for such dramatic
changes in every case. Indeed by using 5 alternate forms of the SDMT,
a previous study did not ﬁnd noticeable diﬀerences (Benedict et al.,
2012).
Next, we examined confounding factors, which could inﬂuence
cognition and the observed practice eﬀect during natalizumab treat-
ment. Disability measured by EDSS inﬂuenced SDMT results. First,
baseline SDMT scores were signiﬁcantly lower in patients with EDSS≥6
compared to cohorts with lower EDSS. This is consistent with earlier
ﬁndings that higher EDSS scores correlate with worse performance in
diﬀerent neuropsychiatric tests (Amato et al., 1995). Although SDMT
scores were signiﬁcantly higher after 2.5 years in this subgroup, still the
net increase in SDMT scores was signiﬁcantly lower compared to
patients with EDSS 0–3, indicating less practice eﬀect. This could be
related to continuous cognitive decline per se and/or to a decreased
ability to gain practice during SDMT. It is possible that patients with
Fig. 5. Eﬀect of relapses and previous natalizumab treatment on SDMT scores. SDMT scores before introduction of regular monthly SDMT (Baseline), 2 years after monthly
SDMT (Year 2) and with the new key are shown. A. SDMT scores in the cohorts of patients who did or did not suﬀer from relapses. B. SDMT scores in a cohort of patients treated with
natalizumab before monthly introduction of SDMT (mean duration of treatment 21.9 ± 20.2 weeks) and in a cohort of patients, who simultaneously started natalizumab and regular
SDMT testing.
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advanced disease are no longer able to increase their processing speed
as much as less aﬀected patients. Both grey matter and white matter
pathology may contribute to such eﬀects as the disease progresses:
cortical lesion number, volume and white matter lesion volume
independently predicted the performance of information processing
speed and working memory, which is measured by SDMT (Mike et al.,
2011; Mike and Illes, 2013). Cortical lesion number also predicted
verbal learning and memory (Mike et al., 2011; Mike and Illes, 2013;
Roosendaal et al., 2009); grey matter pathology becomes prominent
with advanced disease and higher EDSS (Kutzelnigg et al., 2005;
Lassmann, 2007). Cognitive decline predict a more progressive disease
course and seem to be more severe in patients with chronic progressive
disease compared to those in the relapsing-remitting stage (Patti et al.,
2009; Portaccio et al., 2009; Zipoli et al., 2010). Patients with disability
progression, stable disease or improvement also had a signiﬁcant
increase in SDMT scores. But all these cohorts acquired practice eﬀect,
indicated by reversal of scores to baseline when using the rearranged
key. These data altogether may suggest that patients with higher EDSS
may have a deﬁciency in processing speed, working memory and ability
to acquire practice reﬂected by less increase in SDMT scores after 2.5
years. Nevertheless, there is a practice eﬀect in all EDSS groups.
Four out of ten patients suﬀered from at least one relapse during
the study period, which corresponds to the relapse rate found at two
years in the natalizumab phase III trial (Polman et al., 2006). We did
not observe a decrease in SDMT scores in patients who experienced
relapses at the end of the study period. Previous data suggested 2–3
months temporary decrease (Benedict et al., 2014; Morrow et al.,
2011).
We observed that longer SDMT testing period resulted in improve-
ment of SDMT scores. However, these patients were also treated longer
with natalizumab, which might have an eﬀect on the practice eﬀect
itself by improving cognition. To examine the eﬀect of natalizumab
treatment on the practice eﬀect and cognition, we compared a cohort
with treatment before monthly introduction of SDMT (21.9± 20.2
months) to a cohort of patients, who simultaneously started natalizu-
mab and regular SDMT testing. After 1 and 1.5 year, there was a
signiﬁcant increase in SDMT scores in both groups; although the
increase was not signiﬁcant after 2 years in the group simultaneously
treated with natalizumab, this can be explained by lack of statistical
power due to the decreasing number of patients. Scores reversed to
baseline in both cohorts indicating practice eﬀect. Nevertheless, since
these scores were not less than baseline values, this indicated that
processing speed and working memory did not decline during this
period even in patients with EDSS≥6 or disability progression. Indeed,
the eﬀect of natalizumab on cognition has been shown by other
cognitive approaches without practice eﬀect (Iaﬀaldano et al., 2012;
Weinstock-Guttman et al., 2012). Second, the observed continuously
improving practice eﬀect during natalizumab treatment may be related
to maintained cognitive domains.
In summary, our data indicate that repeated monthly testing with
SDMT results in a continuous improvement of SDMT scores up to 35
months during natalizumab treatment, which is less pronounced in
patients with more advanced disease. Such improvement in perfor-
mance is largely attributed to a practice eﬀect. Although SDMT is a
convenient screening tool for early signs of PML, if consecutively
performed, rearrangement of key could make the results more reliable.
Finally, the maintained SDMT scores after 2 years compared to
baseline and the continuously improving practice eﬀect up to 38
months could be related to the eﬀect of natalizumab on cognitive
domains, but this cannot be formally concluded from this retrospective
study due to lack of controls without natalizumab treatment.
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Discussion	
	
Reason	for	conduct	of	Thesis	
	
This	 study	 focuses	 on	 some	 of	 the	 most	 severe	 symptoms	 of	 MS1-3	 -	 fatigue	 and	 cognitive	
impairment	-	and	their	currently	available	rating	scales.	Although	there	are	well-developed	rating	
tools	 and	 objective	 scales	 for	 cognition	 that	 can	 be	 administered	 by	 neuropsychologists,	
physicians,	and	nurses,	regularly	applied	self-reported	tests	would	offer	cost-effective	alternative	
screening	methods.	 In	 contrast,	 fatigue	can	be	measured	only	by	 self-report.	 Implementation	 in	
trials	 and	 daily	 clinical	 practice	 relies	 on	 the	 translation	 and	 validation	 of	 self-reported	
questionnaires.		
	
Fatigue		
Since	outcomes	may	be	biased	by	cultural	and	linguistic	differences,	it	is	essential	that	translated	
PROs	are	 validated	 in	a	 cohort	 that	 represents	 the	native	population.	We	compared	our	 cohort	
with	the	original	German	study	cohort	used	for	validation	of	the	FSMC4,		the	MFIS	as	the	anchor	
point.5	To	date,	the	FMSC	has	been	validated	only	in	German	and	Danish	MS	populations.		
Whereas	the	two	cohorts	were	equivalent	regarding	gender,	the	Danish	cohort	was	slightly	more	
severely	disabled.	 Its	higher	EDSS	scores	could	be	explained	by	older	age	 (7.7	years	on	average)	
and	longer	disease	duration.		
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We	 calculated	 and	 found	 excellent	 internal	 consistency,	 as	 did	 Penner	 et	 al.	 in	 their	 validation	
study4,	 thus	 demonstrating	 the	 interrelatedness	 of	 items	 and	 the	 homogeneity	 of	 scale	 and	
subscales.	The	optimal	alpha	value	has,	however,	been	debated,	with	some	statisticians	suggesting	
that	high	values	(>	0.90)	may	indicate	redundancy6.		
Similarly	with	the	previous	validation	of	the	FSMC,	we	found	high	convergent	validity	and	strong	
positive	correlations	among	FSMC	and	MFIS	and	their	subscales.4	Rather	than	using	the	patient-
reported	 MFIS,	 an	 objective	 anchor	 point	 of	 fatigue	 may	 have	 been	 preferable.	 However,	 no	
studies	have	 succeeded	 in	 establishing	 the	 connection	between	 fatigue	and	biomarkers	 such	as	
inflammatory	CSF	changes,	neurophysiology	examination,	or	structural	brain	damage	measured	by	
MRI.7	At	present,	PROs	thus	offer	the	best	indicators	of	fatigue.		
As	expected,	both	motor	subscales	showed	significant	correlations	with	the	EDSS,	though	only	at	a	
weak	to	moderate	level.	We	found	no	correlation	between	FSMC	and	its	cognitive	subscales	with	
the	BDI-FS	 score,	which	 supports	 the	 use	 of	 the	 FSMC,	 since	many	PROs	 are	 affected	by	mood	
disorders.8	A	sex-based	stratification	showed	that	women	reported	higher	levels	of	fatigue	on	the	
FSMC	motor	subscale	(p	<	0.05)	and	the	MFIS	cognitive	subscale	(p	<	0.05).	As	we	are	not	aware	of	
any	 studies	 demonstrating	 higher	 levels	 of	 fatigue	 in	 females	with	MS	 compared	 to	males,	 we	
assume	that	our	findings	may	be	explained	by	false	positives	(type	I	errors)	of	multiple	testing.	
The	fatigue	subscales	did	not	correlate	with	age,	gender	or	EDSS.		
Some	of	 the	MFIS	test	questions	revealed	differences	between	the	Danish	and	German	cohorts.	
While	this	could	also	reflect	a	type	I	error,	 it	may	as	well	suggest	a	superiority	of	the	FSMC	over	
the	MFIS	in	the	Danish	MS	population,	since	equal	mean	scores	for	the	individual	FSMC	questions	
were	obtained.	
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When	 comparing	 sensitivity	 and	 specificity	 for	 the	 different	 cut-off	 values	 for	 mild	 (≥	 43),	
moderate	 (≥	 53),	 or	 severe	 (≥	 63)	 fatigue	 in	 the	 Danish	 and	 German	 cohorts,	 the	 results	 were	
similar,	 supporting	 the	 application	 of	 the	 original	 German	 cut-off	 values	 in	 Danish	 patients.	
Excellent	test	accuracy	was	found	for	the	area	under	the	curve,	indicating	high	reliability	in	terms	
of	identifying	patients	with	and	without	fatigue9,	10.	A	bias	may	lie	in	lack	of	a	perfect	anchor	point	
(MFIS)	to	distinguish	the	presence	of	the	symptom.		
Our	study	has	some	limitations.	First,	we	had	no	healthy	Danish	control	group.	Second,	we	were	
unable	to	check	for	test-retest	reliability.	Third,	the	MFIS	has	not	been	validated	in	Denmark.		
In	conclusion,	besides	excellent	internal	consistency	and	accuracy,	the	FSMC	has	high	convergent	
validity	with	another	measure	of	fatigue	(MFIS).	Our	results	indicate	that	the	FSMC	is	an	applicable	
and	recommendable	measure	of	fatigue	in	Danish	MS	patients.		
	
Self-reported	cognition		
Following	the	validation	of	the	FSMC,	we	created	a	Danish	version	of	the	MSNQ	and	validated	it	in	
a	 Danish	 MS	 cohort.	 We	 found	 good	 test–retest	 reliability,	 but	 no	 significant	 correlation	 with	
cognitive	impairment	as	measured	by	five	different	gold	standard	neuropsychological	tests	similar	
to	BICAMS.11	Our	results	contrast	with	positive	validation	studies	published	in	Argentine	Spanish,	
Dutch,	 and	 American	 English,12-15	 as	 we	 were	 unable	 to	 establish	 correlation	 between	 MSNQ	
results	 and	 any	 of	 the	 applied	 neuropsychological	 tests.	 The	 SDMT	 seems	 a	 better	 choice	 for	
screening	 for	 cognitive	 impairment,	 as	 four	 out	 of	 five	 neuropsychological	 tests	 showed	 good	
correlation	 with	 SDMT	 again	 in	 contrast	 to	 the	 MSNQ	 that	 didn’t	 correlated	 with	 any	 of	 the	
neuropsychological	 tests.
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We	speculate	that	the	study	may	have	been	underpowered,	since	the	majority	of	patients	were	
within	 the	 normal	 range	 of	 cognitive	 performance,	 as	 determined	 by	 Z-scores	 in	 the	 five	
neuropsychological	tests.	Another	possibility	is	that	the	MSNQ	questions	may	be	unsuitable	for	a	
Danish	population.	 In	our	 fatigue	validation	study,	we	 found	different	scores	 for	 the	Danish	and	
German	 cohorts	 on	 a	 number	 of	 questions.	 The	 Dutch	 validation	 study	 of	 MSNQ16	 also	
demonstrated	differences	in	the	weighting	of	individual	questions	and	MSNQ	scores.	Differences	
in	 demographics	 and	 culture	 of	 study	 cohorts	 with	 regard	 to	 the	 interpretation	 of	 questions	
should	therefore	be	considered.	 In	contrast	to	our	fatigue	validation	study,	we	were	not	able	to	
compare	the	Danish	cohort	with	the	original	MSNQ	validation	cohort,	because	those	data	are	not	
public.	 	The	most	recent	validation	of	the	MSNQ	in	another	language	was	published	in	2009.15	A	
publication	bias	may	be	also	considered,	as	negative	results	in	other	languages	may	not	have	been	
published.17,	18	
The	low	sensitivity	and	specificity	of	the	MSNQ	in	our	study	may	have	several	explanations.	While	
we	used	 the	 same	MSNQ	 cut-off	 value	of	 26	 as	 the	original	 validation	 study,19	 different	 cut-off	
values	were	applied	by	other	studies	to	achieve	higher	sensitivity	and	specificity;	the	optimal	cut-
off	point	thus	seems	to	change	from	study	to	study.14-16	Tests	using	other	cut-off	points	failed	to	
increase	the	sensitivity	or	specificity	in	our	cohort.		
In	 comparison	with	 previous	 studies,	 our	 cohort	 had	 a	 shorter	 average	 disease	 duration	 (eight	
years)	 and	 lower	 disability	 (2.8	 EDSS).	 This	 may	 also	 explain	 our	 relatively	 low	 proportion	 of	
cognitively	impaired	patients	(13	out	of	77)	14-16.	However,	a	sensitive	screening	tool	for	cognitive	
impairment	in	younger	MS	cohorts	and	in	patients	with	shorter	disease	duration	would	be	useful.	
Ideally,	longitudinal	examinations	and	repeated	testing	should	be	preferable	even	in	patients	with	
normal	cognition	in	order	to	assess	cognitive	decline.	
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Most	MS	patients	have	normal	intellect	before	disease	onset,	which	is	usually	in	early	adulthood.	
High	brain	reserve	protects	against	cognitive	impairment	in	MS.20	The	cross-sectional	study	design	
presents	 a	 limitation;	 we	 thus	 failed	 to	 address	 the	 possibility	 that	MSNQ	may	 detect	 relative	
change	 in	 cognition	 over	 time;	 patients	 performing	 above	 the	 50th	 percentile	who	 lose	 1.5	 SD	
would	thus	not	be	detected	with	the	current	definition,	as	they	remained	within	the	normal	range	
(1.5SD	 below	 average)	 of	 cognitive	 impairment.	 This,	 however,	 seems	 unlikely	 and	would	 be	 a	
problem	in	all	studies	with	cross-sectional	designs.	
Finally,	it	should	be	considered	whether	the	MSNQ	offers	a	true	measure	of	cognitive	impairment.	
Self-reported	 cognition	 measures	 show	 poor	 correlation	 with	 systematic	 neuropsychological	
testing.	One	previous	study	has	shown	better	correlation	with	quality	of	life	and	behavioral	data8	
than	 systematic	 neuropsychological	 testing	 and	 MSNQ.	 We	 thus	 found	 that	 both	 MSNQ-I	 and	
MSNQ-P	correlated	significantly	with	BDI	scores.	Other	studies	have	likewise	suggested	that	MSNQ	
is	influenced	by	psychosocial	variables,	such	as	anxiety14,	21,	22.	The	impact	of	psychosocial	variables	
could	 explain	 the	 high	 impact	 on	 self-experienced	 cognitive	 impairment	 reported	 by	 the	
subpopulation	of	the	patients	who	showed	normal	results	on	standard	neuropsychological	testing.		
Interestingly,	another	subgroup,	with	 low	MSNQ-I	and	MSNQ-P	scores,	 showed	severe	cognitive	
impairment	when	 tested	with	 formal	 neuropsychological	 tests.	 This	may	 reflect	 the	 informants’	
coping	 strategy	 resulting	 in	 an	 underestimation	 of	 cognitive	 impairment.	 An	 alternative	
explanation	 for	 low	 MSNQ-P	 and	 high	 cognitive	 impairment	 could	 be	 that	 severely	 affected	
patients	 do	not	 perceive	 dementia.	 Further	 studies	 are	 needed	 to	 clarify	 these	 issues	 raised	by	
self-assessment	of	cognition.	
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In	contrast	to	our	findings	regarding	the	MSNQ,	we	found	a	strong	significant	correlation	between	
SDMT	 and	 neuropsychological	 test	 battery	 scores,	 which	 demonstrates	 the	 relevance	 of	 the	
former	 for	 daily	 clinical	 monitoring	 of	 cognitive	 impairment	 in	 MS,	 and	 shows	 that	 the	 SDMT	
results	are	similar	to	those	of	other	MS	cohorts23-26.	
In	 conclusion,	 whereas	 our	 study	 does	 not	 support	 the	 use	 of	 the	 MSNQ-P	 or	 MSNQ-I	 as	
sufficiently	 valid	 or	 sensitive	 screening	 tools	 for	 cognitive	 impairment	 in	 Danish	MS	 patients,	 it	
does	 show	 that	 the	 higher	 sensitivity	 and	 specificity	 of	 the	 SDMT	 makes	 it	 a	 more	 reliable	
measure.	Further	studies	are	needed	to	assess	the	impact	of	cultural	and	psychosocial	differences	
in	study	populations,	and	the	impact	of	cut-off	values	in	different	populations.		
	
Objective	measures	of	cognition		
In	 our	 examination	 of	 long-term	 changes	 in	 SDMT	 scores	 during	 natalizumab	 treatment,	 we	
observed	a	continuous	increase	in	scores	when	the	test	was	performed	every	month	for	2.5	years.	
The	highest	increases	were	seen	during	the	first	six	months	of	testing,	but	mean	scores	continued	
to	increase	by	about	0.4	point	per	test.	Similar	results	have	been	reported	in	a	48-week	study,	in	
which	 the	 steepness	of	 the	 slope	also	declined	over	 time24.	 Studies	using	 yearly	or	 twice-yearly	
testing	rather	than	monthly	testing,	also	demonstrated	significant	improvement	after	two	years27,	
28.	Two	explanations	are	possible	for	the	continuous	increase	in	SDMT	scores	during	natalizumab	
treatment:	First,	 they	may	be	caused	by	 the	practice	effect	gained	by	performing	 the	same	test	
every	month.	 Second,	 the	 possible	 effect	 of	 treatment	 on	 cognition	may	 reach	 a	 plateau,	 after	
which	only	minor	improvements	occur.	
	 53	
We	therefore	explored	the	effect	of	a	new	key	on	SDMT	performance:	we	examined	confounding	
factors	related	to	the	disease,	and	addressed	the	effects	of	natalizumab	administered	prior	to	the	
introduction	of	regular	monthly	SDMT	testing.	In	a	previous	paper,	Benedict	et	al29	examined	the	
effects	 of	 an	 alternate	 version	 of	 SDMT	 in	 a	 longitudinal	 study;	 we	 examined	 the	 change	 in	
monthly	SDMT	scores,	and	evaluated	the	change	with	an	alternate	SDMT	version.		
We	found	that	a	simple	change	in	the	order	of	the	symbols	reversed	the	increase	in	SDMT	scores	
to	 baseline	 values,	 indicating	 a	 significant	 practice	 effect	 of	 frequent	 testing	 with	 SDM	 during	
natalizumab	 treatment.	 Longer	 testing	 periods	 resulted	 in	 greater	 improvements	 in	 SDMT	
performance,	which	also	supports	the	existence	of	a	practice	effect.	Memorization	of	test	stimuli	
or	 familiarity	with	 the	process	 itself	may	be	 involved.	However,	 if	only	 familiarity	plays	a	 role,	a	
single	change	after	frequent	testing	over	more	than	two	years	should	not	completely	abrogate	the	
effect.	 Patients	may	 also	have	difficulty	 adapting	 to	 a	 new	key.	However,	 it	 is	 unlikely	 that	 this	
would	be	responsible	for	the	consistently	large	changes	observed.	Indeed,	by	using	five	alternate	
forms	of	 the	SDMT,	a	previous	study	by	Benedicte	et	al.	did	not	 find	noticeable	differences29.	A	
study	 published	 subsequent	 to	 our	 paper	 demonstrated	 stable	 SDMT	 scores	 over	 two	 years	 of	
treatment	with	natalizumab,	when	using	five	different	SDMT	keys30.	Such	improvements	in	SDMT	
due	 to	 practice	 effect	 should	 be	 considered	 in	 trial	 designs	 and	 in	measuring	 changes	 in	 SDMT	
scores	over	 time.	 In	 a	 study	designed	with	 a	baseline	 SDMT,	 the	 same	SDMT	was	administered	
again	after	4	weeks,	reporting	increasing	scores	for	subgroups	of	MS	patients	treated	with	slow-
release	 fampridine.	 The	 improvement	 in	 scores	 observed	 in	 that	 study	 is	 similar	 to	 our	 results,	
making	it	unlikely	that	the	slow-release	fampridine	improved	SDMT	scores	on	a	group	level31,	32.	
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Next,	we	examined	 confounding	 factors	 that	might	 influence	 cognition,	 the	practice	 effect,	 and	
explain	the	changes	observed	in	SDMT	during	natalizumab	treatment.	Disability,	as	measured	by	
EDSS,	 was	 found	 to	 influence	 the	 baseline	 SDMT	 and	 also	 the	 practice	 effect.	 Baseline	 SDMT	
scores	were	 significantly	 lower	 in	 patients	with	 EDSS	 ≥	 6	 compare	 to	 patients	with	 lower	 EDSS	
scores.	 This	 is	 consistent	 with	 earlier	 findings	 that	 higher	 EDSS	 scores	 correlate	 with	 poorer	
performance	 in	a	 range	of	neuropsychiatric	 tests1.	Although	SDMT	scores	 	 in	 the	more	disabled	
subgroups	 also	 showed	 an	 increase	 for	 2.5	 years,	 the	 net	 increase	 in	 scores	 was	 significantly	
smaller	 in	 these	 groups	 than	 in	 patients	 with	 EDSS	 scores	 between	 0	 and	 3,	 which	 indicates	 a	
smaller	practice	effect.	This	could	be	 related	 to	cognitive	worsening	or	 to	a	decreased	ability	 to	
profit	from	practice	during	SDMT,	so	that	patients	with	advanced	disease	are	unable	to	 increase	
their	processing	speed	as	much	as	less	affected	patients.	With	progress	of	the	disease,	both	grey	
matter	and	white	matter	pathology	may	contribute	to	such	effects.	Both	the	extent	and	severity	of	
cortical	 and	 white	 matter	 lesions	 independently	 predicted	 information	 processing	 speed	 and	
working	 memory	 performance,	 which	 are	 measured	 by	 SDMT33.	 The	 number	 of	 cortical	 lesion	
attacks	also	predicted	verbal	learning	and	memory33,	34;	grey	matter	pathology	has	been	found	to	
gain	prominence	with	advanced	disease	and	higher	EDSS	scores35,	36.	Cognitive	decline	predicts	a	
more	 progressive	 disease	 course	 and	 seems	 to	 be	 more	 severe	 in	 patients	 with	 chronic	
progressive	 disease	 than	 in	 those	 in	 the	 relapsing-remitting	 stage37-39.	 Taken	 together,	 the	 data	
suggest	that	patients	with	higher	EDSS	scores	may	have	deficiencies	in	processing	speed,	working	
memory,	and	the	ability	to	acquire	practice,	reflected	by	a	smaller	increase	in	SDMT	scores	after	
2.5	years.	Nevertheless,	a	practice	effect	was	demonstrated	in	all	EDSS	groups.		
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Four	out	of	ten	patients	 in	our	study	suffered	from	at	 least	one	relapse	during	the	study	period,	
which	corresponds	to	the	relapse	rate	found	at	two	years	in	the	natalizumab	phase	III	trial40.	We	
did	not	observe	a	decrease	 in	SDMT	scores	at	 the	end	of	 the	study	period	among	patients	who	
experienced	 relapses	 during	 the	 study,	 though	 previous	 data	 suggested	 a	 temporary	 decrease	
lasting	2–3	months41,	42.	 The	underreporting	of	 relapse	 activity	may	 indicate	bias,	 since	patients	
experience	milder	relapses	during	natalizumab	treatment,	leading	to	a	possible	underestimation	in	
retrospective	studies43,	44.	
To	examine	the	effect	of	 treatment	on	the	practice	effect	and	cognition,	we	compared	a	cohort	
who	received	natalizumab	before	the	introduction	of	monthly	SDM	testing	(21.9	±	20.2	months)	to	
a	 cohort	 that	 started	 natalizumab	 and	 regular	 SDMT	 testing	 simultaneously.	 After	 12	 and	 18	
months,	 both	 groups	 showed	 significant	 increases	 in	 SDMT	 scores.	 Although	 the	 second	 group	
showed	 non-significant	 increases	 after	 two	 years,	 this	 can	 be	 explained	 by	 a	 lack	 of	 statistical	
power	 due	 to	 the	 decreasing	 number	 of	 subjects.	 The	 practice	 effect	 was	 indicated	 by	 the	
reverting	of	scores	to	baseline	in	both	cohorts.	Nevertheless,	since	the	scores	after	re-testing	with	
the	 new	 key	 never	 declined	 below	 baseline	 values,	 we	 conclude	 that	 processing	 speed	 and	
working	memory	 did	 not	worsen	 during	 the	 treatment,	 even	 in	 patients	with	 EDSS	 ≥	 6	 or	with	
disability	 progression.	 Indeed,	 the	 effect	 of	 natalizumab	on	 cognition	 has	 been	 shown	by	 other	
studies	 but	 the	 learning	 effect	 has	 not	 been	 considered	 before28,	 45.	 Second,	 the	 continuous	
improvement	 in	 the	 practice	 effect	 during	 natalizumab	 treatment	 may	 also	 be	 related	 to	
maintained	cognitive	domains.		
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In	 summary,	 our	 data	 indicate	 that	 patients	 in	 natalizumab	 treatment	 will	 show	 continuous	
improvement	of	SDMT	results	up	to	35	months	with	repeated	monthly	testing.	The	increase	is	less	
pronounced	 in	 patients	with	more	 advanced	disease.	 Such	performance	 improvement	 is	 largely	
attributed	 to	 a	 practice	 effect.	 Although	 SDMT	 is	 a	 convenient	 screening	 tool	 for	 early	 signs	 of	
PML,	if	consecutively	performed,	the	rearrangement	of	keys	is	likely	to	offer	more	reliable	results,	
even	though	a	certain	practice	effect	has	been	observed	even	when	five	different	SDMT	versions	
were	 used.30	 The	maintenance	 of	 SDMT	 scores	 after	 two	 years	 compared	 to	 baseline,	 and	 the	
continuously	 improving	 practice	 effect	 up	 to	 38	 months,	 could	 be	 related	 to	 the	 effects	 of	
natalizumab	on	cognitive	domains,	although	the	 lack	of	controls	without	natalizumab	treatment	
prevents	us	from	drawing	a	formal	conclusion	from	this	retrospective	study.	Finally,	the	practice	
effect	itself	may	reflect	cognitive	capacities;	consideration	as	a	cognitive	tool	may	be	interesting	to	
test.	
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Practice	points	based	on	results	
	
FSMC	
§ The	FSMC	is	an	applicable	measure	of	fatigue	in	Danish	MS	patients.	
§ The	Danish	FSMC	correlated	well	with	the	original	validation	of	the	scale.	
§ The	FSMC	had	a	high	reliability	and	internal	consistency	in	the	Danish	cohort.	
	
MSNQ	
§ Test–retest	reliability	of	the	MSNQ	patient	self-report	version	was	found	to	be	high.	There	
was	a	high	correlation	between	MSNQ-Patient	and	MSNQ-Informant.	
§ The	Danish	version	of	MSNQ	showed	no	correlation	with	neuropsychological	testing,	which	
may	debate	its	application	in	the	Danish	population.		
§ The	 Danish	 MSNQ	 demonstrated	 significant	 (albeit	 low)	 correlation	 with	 depression,	
suggesting	 a	 correlation	 with	 behavioral	 outcomes	 rather	 than	 with	 neuropsychological	
measures.	
§ Validation	 studies	 in	 the	 native	 language	 are	 needed	 before	 implementation	 in	 clinical	
situations	or	 in	scientific	studies	in	order	to	avoid	false	positive	results	related	to	cultural	
and	linguistic	differences.	
	
SDMT	
• Monthly	SDMT	scores	improve	continuously	in	patients	with	MS,	even	after	two	years.	
• Using	a	new	key	reverts	SDMR	scores	to	baseline,	indicating	a	practice	effect.	
• A	change	of	key	is	required	with	repeated	application	of	SDMT.	
• The	practice	 effect	was	unrelated	 to	 age,	 relapses,	 and	previous	natalizumab	 treatment,	
but	was	affected	by	disability.	
• Cognition	measured	by	SDMT	was	stable	over	two	years	on	natalizumab	treatment.	
